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reamble
is essential that the medical profession play a central role in
itically evaluating the evidence related to drugs, devices,
d procedures for the detection, management, or prevention
disease. Properly applied, rigorous, expert analysis of the
ailable data documenting absolute and relative benefits and
sks of these therapies and procedures can improve the
fectiveness of care, optimize patient outcomes, and favor-
ly affect the cost of care by focusing resources on the most
fective strategies. One important use of such data is the
oduction of clinical practice guidelines that, in turn, can
ovide a foundation for a variety of other applications such
performance measures, appropriateness use criteria, clini-
l decision support tools, and quality improvement tools.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly
gaged in the production of guidelines in the area of
rdiovascular disease since 1980. The ACCF/AHA Task
orce on Practice Guidelines (Task Force) is charged with
veloping, updating, and revising practice guidelines for
rdiovascular diseases and procedures, and the Task Force
rects and oversees this effort. Writing committees are
arged with assessing the evidence as an independent group
authors to develop, update, or revise recommendations for
inical practice.
Experts in the subject under consideration have been
lected from both organizations to examine subject-specific
ta and write guidelines in partnership with representatives
om other medical practitioner and specialty groups. Writing
mmittees are specifically charged to perform a formal
terature review, weigh the strength of evidence for or
ainst particular tests, treatments, or procedures, and include
timates of expected health outcomes where data exist.
atient-specific modifiers, comorbidities, and issues of pa-
ent preference that may influence the choice of tests or
erapies are considered. When available, information from
udies on cost is considered, but data on efficacy and clinical
tcomes constitute the primary basis for recommendations
these guidelines.
In analyzing the data and developing the recommendations
d supporting text, the writing committee used evidence- wsed methodologies developed by the Task Force, which are
scribed elsewhere (1). The committee reviewed and ranked
idence supporting current recommendations with the
eight of evidence ranked as Level A if the data were derived
om multiple randomized clinical trials (RCTs) or meta-
alyses. The committee ranked available evidence as Level
when data were derived from a single RCT or nonrandom-
ed studies. Evidence was ranked as Level C when the
imary source of the recommendation was consensus opin-
n, case studies, or standard of care. In the narrative portions
these guidelines, evidence is generally presented in chro-
logical order of development. Studies are identified as
servational, retrospective, prospective, or randomized
hen appropriate. For certain conditions for which inade-
ate data are available, recommendations are based on
pert consensus and clinical experience and ranked as Level
. An example is the use of penicillin for pneumococcal
eumonia, for which there are no RCTs and treatment is
sed on clinical experience. When recommendations at
evel C are supported by historical clinical data, appropriate
ferences (including clinical reviews) are cited if available.
or issues where sparse data are available, a survey of current
actice among the clinicians on the writing committee was
e basis for Level C recommendations and no references are
ted. The schema for Classification of Recommendations and
evel of Evidence is summarized in Table 1, which also
lustrates how the grading system provides an estimate of the
ze and the certainty of the treatment effect. A new addition
the ACCF/AHA methodology is separation of the Class III
commendations to delineate whether the recommendation
determined to be of “no benefit” or associated with “harm”
the patient. In addition, in view of the increasing number of
mparative effectiveness studies, comparator verbs and sug-
sted phrases for writing recommendations for the compar-
ive effectiveness of one treatment/strategy with respect to
other for Class of Recommendation I and IIa, Level of
vidence A or B only have been added.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
relationships with industry and other entities (RWI) among
e writing committee. Specifically, all members of the
riting committee, as well as peer reviewers of the document,
e required to disclose all relevant relationships and those 12
onths prior to initiation of the writing effort. The policies
d procedures for RWI for this guideline were those in effect
the initial meeting of this committee (March 28, 2009),
hich included 50% of the writing committee with no
levant RWI. All guideline recommendations require a
nfidential vote by the writing committee and must be
proved by a consensus of the members voting. Members
ho were recused from voting are indicated on the title page
this document with detailed information included in
ppendix 1. Members must recuse themselves from voting
any recommendations where their RWI apply. If a writing
mmittee member develops a new RWI during his/her
nure, he/she is required to notify guideline staff in writing.
hese statements are reviewed by the Task Force and all
embers during each conference call and/or meeting of the
riting committee and are updated as changes occur. For
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res, please refer to the ACCF/AHA methodology and
licies manual (1). RWI pertinent to this guideline for
thors and peer reviewers are disclosed in Appendixes 1 and
respectively. Comprehensive disclosure information for the
ask Force is also available online at http://www.cardiosource.
g/ACC/About-ACC/Leadership/Guidelines-and-Documents-
ask-Forces.aspx. The work of the writing committee was
pported exclusively by the ACCF and AHA without com-
ercial support. Writing committee members volunteered
eir time for this effort.
The ACCF/AHA practice guidelines address patient
BLE 1. Applying Classification of Recommendation and Level
A recommendation with Level of Evidence B or C does not imply that the reco
not lend themselves to clinical trials. Although randomized trials are unavaila
eful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.pulations (and healthcare providers) residing in North dimerica. As such, drugs that are currently unavailable in
orth America are discussed in the text without a specific
ass of recommendation. For studies performed in large
mbers of subjects outside of North America, each
riting group reviews the potential impact of different
actice patterns and patient populations on the treatment
fect and on the relevance to the ACCF/AHA target
pulation to determine whether the findings should in-
rm a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches for the
ence
ation is weak. Many important clinical questions addressed in the guidelines
re may be a very clear clinical consensus that a particular test or therapy is
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involveof Evid
mmend
ble, the
in diffe
dence Aagnosis, management, and prevention of specific diseases
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expert opinion after a thorough review of the available
rrent scientific evidence and are intended to improve
tient care. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment regarding care of a particular patient must
made by the healthcare provider and patient in light of all
e circumstances presented by that patient. Thus, there are
tuations in which deviations from these guidelines may be
propriate. Clinical decision making should consider the
ality and availability of expertise in the area where care is
ovided. When these guidelines are used as the basis for
gulatory or payer decisions, the goal should be improve-
ent in quality of care. The Task Force recognizes that
tuations arise for which additional data are needed to better
form patient care; these areas will be identified within each
spective guideline when appropriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect outcomes, physicians and other healthcare
oviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and
festyles.
The guideline will be reviewed annually by the Task Force
d considered current unless it is updated, revised, or
ithdrawn from distribution. Guidelines are official policy of
th the ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he recommendations listed in this document are, whenever
ssible, evidence based. An extensive evidence review was
nducted through January 2011. Searches were limited to
udies, reviews, and other evidence conducted in human
bjects and published in English. Key search words in-
uded, but were not limited to, hypertrophic cardiomyopathy
CM), surgical myectomy, ablation, exercise, sudden car-
ac death (SCD), athletes, dual-chamber pacing, left ven-
icular outflow tract (LVOT) obstruction, alcohol septal
lation, automobile driving and implantable cardioverter-
fibrillators (ICDs), catheter ablation, defibrillators, genet-
s, genotype, medical management, magnetic resonance
aging, pacing, permanent pacing, phenotype, pregnancy,
sk stratification, sudden death in athletes, surgical septal
yectomy, and septal reduction. Additionally, the committee
viewed documents related to the subject matter previously
blished by the ACCF and AHA. References selected and
blished in this document are representative and not all-
clusive.
To provide clinicians with a comprehensive set of data,
henever deemed appropriate or when published, the abso-
te risk difference and number needed to treat or harm are
ovided in the guideline, along with confidence intervals and itta related to the relative treatment effects, such as odds
tio, relative risk, hazard ratio, or incidence rate ratio.
.2. Organization of the Writing Committee
he committee was composed of physicians and cardiac
rgeons with expertise in HCM, invasive cardiology, non-
vasive testing and imaging, pediatric cardiology, electro-
ysiology, and genetics. The committee included represen-
tives from the American Association for Thoracic Surgery,
merican Society of Echocardiography, American Society of
uclear Cardiology, Heart Failure Society of America, Heart
hythm Society, Society for Cardiovascular Angiography
d Interventions, and Society of Thoracic Surgeons.
.3. Document Review and Approval
his document was reviewed by 2 outside reviewers nomi-
ted by both the ACCF and AHA, as well as 2 reviewers
ch from the American Association for Thoracic Surgery,
merican Society of Echocardiography, American Society of
uclear Cardiology, Heart Failure Society of America, Heart
hythm Society, Society for Cardiovascular Angiography
d Interventions, and the Society of Thoracic Surgeons.
ther content reviewers included members from the ACCF
dult Congenital and Pediatric Cardiology Council, ACCF
urgeons’ Scientific Council, and ACCF Interventional Sci-
tific Council. All information on reviewers’ RWI was
stributed to the writing committee and is published in this
cument (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and endorsed by the
merican Association for Thoracic Surgery, American Soci-
y of Echocardiography, American Society of Nuclear Car-
ology, Heart Failure Society of America, Heart Rhythm
ociety, Society for Cardiovascular Angiography and Inter-
ntions, and Society of Thoracic Surgeons.
.4. Scope of the Guideline
lthough there are reports of this disease dating back to the
00s, the first modern pathologic description was provided
er 50 years ago by Teare (2) and the most important early
inical report by Braunwald et al. in 1964 (3). Since then,
ere has been a growing understanding of the complexity
d diversity of the underlying genetic substrate, the clinical
enotype, natural history, and approaches to treatment.
The impetus for the guideline is based on an appreciation
the frequency of this clinical entity and a realization that
any aspects of clinical management, including the use of
agnostic modalities and genetic testing, lack consensus.
oreover, the emergence of 2 different approaches to septal
duction therapy (septal myectomy and alcohol septal abla-
on) in addition to the ICD has created considerable contro-
rsy. The discussion and recommendations about the various
agnostic modalities apply to patients with established HCM
d to a variable extent to patients with a high index of
spicion of the disease.
Although the Task Force was aware of the lack of high
vels of evidence regarding HCM provided by clinical trials,
was believed that a guideline document based on expert
co
m
ti
ap
in
2
D
2
H
ti
st
pr
se
th
pe
fr
re
pr
un
sh
2
2
A
di
en
in
by
no
as
H
ti
in
fu
w
IH
no
us
ti
fo
2
T
th
ch
w
an
ca
a
ar
ou
re
w
ul
fa
of
ha
ca
in
w
of
th

un
co
an
sp
ca
di
in
ti
F
of
re
la
po
H
cl
ty
sy
m
(w
hy
as
T
be
co
m
In
sy
co
by
in
ob
m
tr
at
co
(L
ev
va
hi
at
(i
sh
th
di
an
(a
pl
e217JACC Vol. 58, No. 25, 2011 Gersh et al.
December 13/20, 2011:e212–60 ACCF/AHA Hypertrophic Cardiomyopathy Guidelinensensus that outlines the most important diagnostic and
anagement strategies would be helpful.
To facilitate ease of use, it was decided that recommenda-
ons in the pediatric and adolescent age groups would not
pear as a separate section but instead would be integrated
to the overall content of the guideline where relevant.
. Prevalence/Nomenclature/
ifferential Diagnosis
.1. Prevalence
CM is a common genetic cardiovascular disease. In addi-
on, HCM is a global disease (4), with epidemiological
udies from several parts of the world (5) reporting a similar
evalence of left ventricular (LV) hypertrophy, the quintes-
ntial phenotype of HCM, to be about 0.2% (i.e., 1:500) in
e general population, which is equivalent to at least 600,000
ople affected in the United States (6). This estimated
equency in the general population appears to exceed the
latively uncommon occurrence of HCM in cardiology
actices, implying that most affected individuals remain
identified, probably in most cases without symptoms or
ortened life expectancy.
.2. Nomenclature
.2.1. Historical Context
lthough HCM is the preferred nomenclature to describe this
sease (7), confusion over the names used to characterize the
tity of HCM has arisen over the years. At last count, 80
dividual names, terms, and acronyms have been used (most
early investigators) to describe HCM (7). Furthermore,
menclature that was popular in the 1960s and 1970s, such
IHSS (idiopathic hypertrophic subaortic stenosis) or
OCM (hypertrophic obstructive cardiomyopathy), is poten-
ally confusing by virtue of the inference that LVOT is an
variable and obligatory component of the disease. In fact,
lly one third of patients have no obstruction either at rest or
ith physiologic provocation (8). Although terms such as
SS and HOCM persist occasionally in informal usage, they
w rarely appear in the literature, whereas HCM, initially
ed in 1979, allows for both the obstructive and nonobstruc-
ve hemodynamic forms and has become the predominant
rmal term used to designate this disease (7).
.2.2. Clinical Definition and Differential Diagnosis
he generally accepted definition of HCM, the clinical entity
at is the subject of this guideline, is a disease state
aracterized by unexplained LV hypertrophy associated
ith nondilated ventricular chambers in the absence of
other cardiac or systemic disease that itself would be
pable of producing the magnitude of hypertrophy evident in
given patient (6,7,9–12), with the caveat that patients who
e genotype positive may be phenotypically negative with-
t overt hypertrophy (13,14). Clinically, HCM is usually
cognized by maximal LV wall thickness 15 mm, with
all thickness of 13 to 14 mm considered borderline, partic-
arly in the presence of other compelling information (e.g.,
mily history of HCM), based on echocardiography. In terms FLV wall-thickness measurements, the literature at this time
s been largely focused on echocardiography, although
rdiovascular magnetic resonance (CMR) is now used with
creasing frequency in HCM (15), and we presume that data
ith this latter modality will increasingly emerge. In the case
children, increased LV wall thickness is defined as wall
ickness 2 standard deviations above the mean (z score
2) for age, sex, or body size. However, it should be
derscored that in principle, any degree of wall thickness is
mpatible with the presence of the HCM genetic substrate
d that an emerging subgroup within the broad clinical
ectrum is composed of family members with disease-
using sarcomere mutations but without evidence of the
sease phenotype (i.e., LV hypertrophy) (16–19). These
dividuals are usually referred to as being “genotype posi-
ve/phenotype negative” or as having “subclinical HCM.”
urthermore, although a myriad of patterns and distribution
LV hypertrophy (including diffuse and marked) have been
ported in HCM (15,20,21) about one third of patients have
rgely segmental wall thickening involving only a small
rtion of the left ventricle, and indeed such patients with
CM usually have normal calculated LV mass (15). The
inical diagnosis of HCM may also be buttressed by other
pical features, such as family history of the disease, cardiac
mptoms, tachyarrhythmias, or electrocardiographic abnor-
alities (9,10).
Differential diagnosis of HCM and other cardiac conditions
ith LV hypertrophy) may arise, most commonly with
pertensive heart disease and the physiologic remodeling
sociated with athletic training (“athlete’s heart”) (22–26).
hese are not uncommon clinical scenarios, and confusion
tween mild morphologic expressions of HCM and other
nditions with LV hypertrophy usually arises when maxi-
um wall thickness is in the modest range of 13 to 15 mm.
older patients with LV hypertrophy and a history of
stemic hypertension, coexistence of HCM is often a
nsideration. The likelihood of HCM can be determined
identification of a diagnostic sarcomere mutation or
ferred by marked LV thickness 25 mm and/or LVOT
struction with systolic anterior motion (SAM) and
itral-septal contact.
The important distinction between pathologic LV hyper-
ophy (i.e., HCM) and physiologic LV hypertrophy (i.e.,
hlete’s heart) is impacted by the recognition that athletic
nditioning can produce LV, right ventricular, and left atrial
A) chamber enlargement, ventricular septal thickening, and
en aortic enlargement (26) but is often resolved by nonin-
sive markers, including sarcomeric mutations or family
story of HCM, LV cavity dimension (if enlarged, favoring
hlete’s heart), diastolic function, pattern of LV hypertrophy
f unusual location or noncontiguous, favoring HCM), or
ort deconditioning periods in which a decrease in wall
ickness would favor athlete’s heart (22–26).
Notably, it is evident that metabolic or infiltrative storage
sorders with LV hypertrophy in babies, older children,
d young adults can mimic clinically diagnosed HCM
ttributable to sarcomeric protein mutations), for exam-
e, conditions such as mitochondrial disease (27,28),
abry disease (29), or storage diseases caused by muta-
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enosine monophosphate (AMP)-activated protein kinase
RKAG2) or the X-linked lysosome-associated membrane
otein gene (LAMP2; Danon disease) (30–33). Use of
e term HCM is not appropriate to describe these and other
tients with LV hypertrophy that occurs in the context of a
ultisystem disorder such as Noonan syndrome (with cranio-
cial and congenital heart malformations, as well as LV
pertrophy from mutations in genes of the RAS [RAt
arcoma] pathway [14,15]), or distinct cardiomyopathies
ch as Pompe disease (also a glycogen storage disease II,
ith skeletal muscle weakness and cardiomyopathy because
deficiency of 1,4 glycosidase [acid maltase]) (34–38)
igure 1). In addition, differential diagnosis of HCM may
quire distinction from systemic hypertension or physiologic
hlete’s heart (23) or from dilated cardiomyopathy when
CM presents in the end stage (39).
.2.3. Impact of Genetics
n the basis of the genotype-phenotype data available at this
me, HCM is regarded here as a disease entity caused by
tosomal dominant mutations in genes encoding protein
mponents of the sarcomere and its constituent myofilament
ements (30,40–42). Intergenetic diversity is compounded
considerable intragene heterogeneity, with 1,400 muta-
ons identified among at least 8 genes. The current weight of
idence supports the view that the vast majority of genes and
utations responsible for clinically diagnosed HCM encode
oteins within and associated with the sarcomere, accounting
large measure for those patients described in the volumi-
us amount of HCM literature published over 50 years
0,40–42).
In conclusion, the writing committee believes that the most
udent recommendation for nomenclature is that hypertro-
ic cardiomyopathy and the acronym HCM remain a clinical
agnosis limited to those patients in whom 1) overt disease
pression (with LV hypertrophy) appears to be confined to
e heart and 2) the definitive mutation is either one of a gene
gure 1. Summary of the nomenclature that distinguishes HCM
om other genetic diseases associated with LV hypertrophy. *At
is time the overwhelming evidence links the clinical diagnosis
HCM with a variety of genes encoding protein components of
e cardiac sarcomere. However, it is possible that in the future
her nonsarcomeric (but also nonmetabolic) genes may prove
cause HCM. †An example is Noonan syndrome with cardio-
yopathy. Modified with permission from Maron et al. (12).coding proteins of the cardiac sarcomere or alternativelyhen the genotype is unresolved using current genetic test-
g. Therefore, nomenclature that describes patients as
oonan hypertrophic cardiomyopathy” is discouraged,
hereas “Noonan syndrome with LV hypertrophy” or
oonan syndrome with cardiomyopathy” is preferred.
.2.4. Hypertrophic Cardiomyopathy Centers
he writing committee considers it important to emphasize
at HCM is a complex disease entity with a broad (and
creasing) clinical and genetic spectrum (9). Although HCM
one of the most common forms of genetic heart disease and
latively common in the general population (6), this disease
tity is infrequent in general clinical practice, with most
rdiologists responsible for the care of only a few patients
ith HCM (43). This principle has led to an impetus for
tablishing clinical programs of excellence—usually within
tablished centers—in which cardiovascular care is focused
the management of HCM (i.e., “HCM centers”) (43,44).
uch programs are staffed by cardiologists and cardiac
rgeons familiar with the contemporary management of
CM and offer all diagnostic and treatment options, includ-
g genetic testing and counseling, comprehensive transtho-
cic echocardiogram (TTE), CMR imaging, both surgical
ptal myectomy and alcohol ablation, and the management
atrial fibrillation (AF)/atrial flutter, and ICDs. Another
vantage is the potential to perform outcomes research on
rge groups of patients. Although the writing committee does
t necessarily recommend that all patients with HCM should
evaluated in such centers, nevertheless, it is the strong
ew that patients with this disease may well benefit from a
inical environment with specific expertise in HCM. The
lection of patients for referral to an HCM center should be
sed largely on the judgment of the managing cardiologist
d the degree to which he or she is comfortable advising and
aluating patients with HCM with a particular clinical
ofile.
. Clinical Course and Natural History,
cluding Absence of Complications
CM is a heterogeneous cardiac disease with a diverse
inical presentation and course, presenting in all age groups
om infancy to the very elderly (9,10,39,45). Most affected
dividuals probably achieve a normal life expectancy with-
t disability or the necessity for major therapeutic interven-
ons (46–49). On the other hand, in some patients, HCM is
sociated with disease complications that may be profound,
ith the potential to result in disease progression or prema-
re death (9,10,39,45,50,51). When the disease does result
significant complications, there are 3 relatively discrete
t not mutually exclusive pathways of clinical progression
igure 2):
SCD due to unpredictable ventricular tachyarrhythmias,
most commonly in young asymptomatic patients 35
years of age (50–59) (including competitive athletes)
(58,59).
Heart failure characterized by exertional dyspnea (with or
without chest pain) that may be progressive despite
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proportion of patients, heart failure may progress to the
end stage with LV remodeling and systolic dysfunction
caused by extensive myocardial scarring (39).
AF, either paroxysmal or chronic, also associated with
various degrees of heart failure (60) and an increased risk
of systemic thromboembolism and both fatal and nonfatal
stroke.
The natural history of HCM can be altered by a number of
erapeutic interventions: ICDs for secondary or primary
evention of sudden death in patients with risk factors
4–56); drugs appropriate to control heart failure symptoms
rincipally those of exertional dyspnea and chest discomfort)
,10), surgical septal myectomy (61) or alcohol septal
lation (62) for progressive and drug-refractory heart failure
used by LVOT obstruction; heart transplantation for sys-
lic (or less frequently intractable diastolic) dysfunction
sociated with severe unrelenting symptoms (39); and drug
erapy or possibly radiofrequency ablation or surgical maze
ocedure for AF (63–65).
. Pathophysiology
he pathophysiology of HCM is complex and consists of
ultiple interrelated abnormalities, including LVOT obstruc-
on, diastolic dysfunction, mitral regurgitation, myocardial
chemia, and arrhythmias (9,66,67). It is clinically important
distinguish between the obstructive and nonobstructive
rms of HCM because management strategies are largely
pendent on the presence or absence of symptoms caused by
struction.
.1. LVOT Obstruction
he original observations by Brock (68) and Braunwald et al.
) emphasized the functional subvalvular LVOT gradient,
hich was highly influenced by alterations in the load and
ntractility of the left ventricle. The clinical significance of
e outflow tract gradient has periodically been controversial
9–72), but careful studies have shown definitively that true
echanical obstruction to outflow does occur (66,67). For
CM, it is the peak instantaneous LV outflow gradient rather
an the mean gradient that influences treatment decisions.
gure 2. Prognosis profiles for HCM and targets for therapy.
F indicates atrial fibrillation. Modified with permission fromesaron et al. (10).hroughout the remainder of this document the term gradient
ill be used to denote peak instantaneous gradient. Up to one
ird of patients with HCM will have obstruction under basal
esting) conditions (defined as gradients 30 mm Hg).
nother one third or more of patients will have labile,
ysiologically provoked gradients (30 mm Hg at rest and
30 mm Hg with physiologic provocation) (8). The final one
ird of patients will have the nonobstructive form of HCM
radients 30 mm Hg at rest and with provocation) (Table 2).
arked gradients 50 mm Hg, either at rest or with provo-
tion, represent the conventional threshold for surgical or
rcutaneous intervention if symptoms cannot be controlled
ith medications.
Obstruction causes an increase in LV systolic pressure,
hich leads to a complex interplay of abnormalities including
olongation of ventricular relaxation, elevation of LV dia-
olic pressure, mitral regurgitation, myocardial ischemia, and
decrease in forward cardiac output (9,66,67). Outflow
struction usually occurs in HCM by virtue of mitral valve
AM and mitral-septal contact. Although the mechanism of
e outflow tract gradient in HCM was initially thought to be
used by systolic contraction of the hypertrophied basal
ntricular septum encroaching on the LVOT, most recent
udies emphasize that during ventricular systole, flow against
e abnormally positioned mitral valve apparatus results in
ag force on a portion of the mitral valve leaflets, which
shes the leaflets into the outflow tract (66,67,75–78).
uscular obstruction can also be present in the midcavitary
gion, occasionally because of hypertrophied papillary mus-
es abutting the septum (79) or anomalous papillary muscle
sertion into the anterior mitral leaflet (80).
Obstruction to LV outflow is dynamic, varying with
ading conditions and contractility of the ventricle (3).
creased myocardial contractility, decreased ventricular vol-
e, or decreased afterload increases the degree of subaortic
struction. Patients may have little or no obstruction of the
VOT at rest but can generate large LVOT gradients under
nditions such as exercise, the strain phase of the Valsalva
aneuver, or during pharmacologic provocation (66,67).
here is often large spontaneous variation in the severity of
e gradient during day-to-day activities or even with food or
cohol intake (81); exacerbation of symptoms during the
stprandial period is common. Importantly, it has been well
ble 2. Definitions of Dynamic Left Ventricular Outflow
act Obstruction
emodynamic State Conditions Outflow Gradient*
sal obstruction Rest 30 mm Hg†
nobstructive Rest 30 mm Hg
Physiologically provoked 30 mm Hg
bile obstruction Rest 30 mm Hg†
Physiologically provoked 30 mm Hg†
*Either the peak instantaneous continuous wave Doppler gradient or the
ak-to-peak cardiac catheterization gradient, which are equivalent in hyper-
phic cardiomyopathy (73,74).
†Gradients50 mm Hg either at rest or with provocation are considered the
reshold for septal reduction therapy in severely symptomatic patients.tablished that LVOT obstruction contributes to the debili-
ta
(6
us
co
ve
ti
de
re
m
be
ec
m
ti
og
ou
ca
fu
w
ou
da
ex
ca
ta
og
4
D
m
m
st
re
fl
tr
ab
ph
st
bo
in
at
ex
th
di
di
in
4
S
H
la
(C
w
by
ha
di
at
na
4
D
ha
fa
in
fi
in
du
ob
sp
pa
as
re
4
M
ob
sy
ej
gi
(6
di
se
gi
du
su
m
by
re
so
th
af
id
va
in
5
T
ca
2-
M
tr
an
m
m
ch
ab
ge
id
H
5
F
CL
1.
e220 Gersh et al. JACC Vol. 58, No. 25, 2011
ACCF/AHA Hypertrophic Cardiomyopathy Guideline December 13/20, 2011:e212–60ting heart failure–related symptoms that may occur in HCM
6,67) and is also a major determinant of outcome (45).
The presence and magnitude of outflow obstruction are
ually assessed with 2-dimensional echocardiography and
ntinuous wave Doppler. It is a late-peaking systolic
locity that reflects the occurrence of subaortic obstruc-
on late in systole, and the peak instantaneous gradient
rived from the peak velocity should be reported. If the
sting outflow gradient is 50 mm Hg, provocative
easures may be used to ascertain if higher gradients can
elicited, preferably with physiologic exercise (stress
hocardiography) but alternatively with the Valsalva
aneuver or selectively with amyl nitrite (3,10). Provoca-
on with dobutamine infusion during Doppler echocardi-
raphy is no longer recommended as a strategy to induce
tflow gradients in HCM. However in equivocal cases,
rdiac catheterization with isoproterenol infusion may
rther aid in eliciting a provocable gradient (82). Other-
ise, routine invasive cardiac catheterization to document
tflow gradients is necessary only when there are discor-
nt data from Doppler echocardiography and the physical
amination (10). The peak-to-peak gradient obtained with
theterization most closely approximates the peak instan-
neous gradient by continuous wave Doppler echocardi-
raphy (73,74).
.2. Diastolic Dysfunction
iastolic dysfunction arising from multiple factors is a
ajor pathophysiologic abnormality in HCM that ulti-
ately affects both ventricular relaxation and chamber
iffness (66,67,83). Impairment of ventricular relaxation
sults from the systolic contraction load caused by out-
ow tract obstruction, nonuniformity of ventricular con-
action and relaxation, and delayed inactivation caused by
normal intracellular calcium reuptake. Severe hypertro-
y of the myocardium results in an increase in chamber
iffness. Diffuse myocardial ischemia may further affect
th relaxation and chamber stiffness. A compensatory
crease in the contribution of late diastolic filling during
rial systole is associated with these alterations (84). With
ercise or any other type of catecholamine stimulation,
e decrease in diastolic filling period as well as myocar-
al ischemia will further lead to severe abnormalities of
astolic filling of the heart, with chest pain and/or an
crease in pulmonary venous pressure causing dyspnea.
.3. Myocardial Ischemia
evere myocardial ischemia and even infarction may occur in
CM (85,86). The myocardial ischemia is frequently unre-
ted to the atherosclerotic epicardial coronary artery disease
AD) but is caused by supply–demand mismatch. Patients
ith HCM of any age have increased oxygen demand caused
the hypertrophy and adverse loading conditions. They also
ve compromised coronary blood flow to the LV myocar-
um because of intramural arterioles with thickened walls
tributable to medial hypertrophy associated with luminal
rrowing (87)..4. Autonomic Dysfunction
uring exercise, approximately 25% of patients with HCM
ve an abnormal blood pressure response defined by either a
ilure of systolic blood pressure to rise 20 mm Hg or a fall
systolic blood pressure (88,89). The presence of this
nding is associated with a poorer prognosis (89,90). This
ability to augment and sustain systolic blood pressure
ring exercise is caused by either the dynamic LVOT
struction or systemic vasodilatation during exercise. It is
eculated that autonomic dysregulation (88) is present in
tients with HCM and that the fall in blood pressure
sociated with bradycardia may be an abnormal reflex
sponse to obstruction.
.5. Mitral Regurgitation
itral regurgitation is common in patients with LVOT
struction and may play a primary role in producing
mptoms of dyspnea. The temporal sequence of events of
ect-obstruct-leak supports the concept that the mitral regur-
tation in most patients is a secondary phenomenon
6,67,91). The mitral regurgitation is usually caused by the
stortion of the mitral valve apparatus from the SAM
condary to the LVOT obstruction. The jet of mitral regur-
tation is directed laterally and posteriorly and predominates
ring mid and late systole. An anteriorly directed jet should
ggest an intrinsic abnormality of the mitral valve. If the
itral regurgitation is caused by distortion of leaflet motion
SAM of the mitral valve, the severity of the mitral
gurgitation may be proportional to the LVOT obstruction in
me patients. Changes in ventricular load and contractility
at affect the severity of outflow tract obstruction similarly
fect the degree of mitral regurgitation. It is important to
entify patients with additional intrinsic disease of the mitral
lve apparatus (prolapse or flail), because this finding
fluences subsequent treatment options (92).
. Diagnosis
he clinical diagnosis of HCM is conventionally made with
rdiac imaging, at present most commonly with
dimensional echocardiography and increasingly with CMR.
orphologic diagnosis is based on the presence of a hyper-
ophied and nondilated left ventricle in the absence of
other cardiac or systemic disease capable of producing the
agnitude of hypertrophy evident in a patient (usually 15
m in adults or the equivalent relative to body surface area in
ildren). Genetic testing, which is now commercially avail-
le, is a powerful strategy for definitive diagnosis of affected
netic status and is currently used most effectively in the
entification of affected relatives in families known to have
CM.
.1. Genetic Testing Strategies/
amily Screening—Recommendations
ASS I
Evaluation of familial inheritance and genetic counseling is
recommended as part of the assessment of patients with HCM
(17,31,93–96). (Level of Evidence: B)
2.
3.
4.
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December 13/20, 2011:e212–60 ACCF/AHA Hypertrophic Cardiomyopathy GuidelinePatients who undergo genetic testing should also undergo
counseling by someone knowledgeable in the genetics of
cardiovascular disease so that results and their clinical
significance can be appropriately reviewed with the patient
(97–101). (Level of Evidence: B)
Screening (clinical, with or without genetic testing) is recom-
mended in first-degree relatives of patients with HCM
(17,31,93,94,96,102,103). (Level of Evidence: B)
Genetic testing for HCM and other genetic causes of unex-
plained cardiac hypertrophy is recommended in patients with
an atypical clinical presentation of HCM or when another
genetic condition is suspected to be the cause (104–106).
(Level of Evidence: B)
ASS IIa
Genetic testing is reasonable in the index patient to facilitate
the identification of first-degree family members at risk for
developing HCM (17,95,102). (Level of Evidence: B)
ASS IIb
The usefulness of genetic testing in the assessment of risk of
SCD in HCM is uncertain (107,108). (Level of Evidence: B)
ASS III: NO BENEFIT
Genetic testing is not indicated in relatives when the index
patient does not have a definitive pathogenic mutation
(17,31,93–96,109). (Level of Evidence: B)
Ongoing clinical screening is not indicated in genotype-
negative relatives in families with HCM (109–112). (Level of
Evidence: B)
e Online Data Supplement 1 for additional data regard-
g genetic testing strategies/family screening.
HCM is caused by an autosomal dominant mutation in
nes that encode sarcomere proteins or sarcomere-
sociated proteins. The most vigorous evidence indicates
at 8 genes are known to definitively cause HCM: beta
yosin heavy chain, myosin binding protein C, troponin T,
oponin I, alpha tropomyosin, actin, regulatory light chain,
d essential light chain (11,12,30,40–42). In addition, ac-
nin and myozenin are associated with less definitive evi-
nce for causing HCM. At this time there is inconclusive
idence to support other genes causing HCM (94,96,113,114),
t research is ongoing and other genetic causes may be
entified (93,115). A single mutation in 1 of the 2 alleles (or
pies) of a gene is sufficient to cause HCM; however, 5% of
tients with HCM have 2 mutations in the same gene or
fferent genes (110,116).
Genetic and/or clinical screening of all first-degree family
embers of patients with HCM is important to identify those
ith unrecognized disease. On the basis of family history,
inical screening, and pedigree analyses, the pattern of
heritance is ascertained to identify and counsel relatives at
sk (101). Because familial HCM is a dominant disorder, the
sk that an affected patient will transmit disease to each
fspring is 50%. When a pathogenic mutation is identified in
index patient, the genetic status of each family member
n be readily ascertained. Because HCM mutations are
ghly penetrant, a mutation conveys substantial (95%) risk ever a lifetime for developing clinical and/or phenotypic
idence of HCM (94,96,113,114).
Genetic counseling before genetic testing will increase
derstanding of the medical and familial implications of test
sults, enabling informed decision making about potential
sks and benefits (98,99). Genetic counseling can also reduce
tential psychologic responses to learning one’s mutation
atus (4,101). Even when genetic testing is not undertaken,
netic counseling about the potential for familial transmis-
on of HCM is medically important.
The occurrence of HCM can be isolated or sporadic, but
e frequency of sporadic HCM is unresolved. Sporadic HCM
n reflect an inaccurate family history, incomplete pen-
rance (absence of clinical expression despite the presence of
mutation) in family members, or a de novo (new) mutation
at can initiate new familial disease (93,115).
Because unrelated patients with HCM will have different
utations, a comprehensive sequence-based analysis of all
CM genes is necessary to define the pathogenic (e.g.,
sease-causing) mutation in an index patient. Experienced
inical laboratories identify the pathogenic HCM mutation in
proximately 60% to 70% of patients with a positive family
story and approximately 10% to 50% of patients without a
mily history (93,102). Genetic testing may identify a
thogenic mutation (e.g., analysis defines a sequence variant
own to cause HCM) or a “likely pathogenic” mutation, a
NA variant that was previously unknown as a cause of
CM but has molecular characteristics that are similar to
cognized HCM mutations. Genetic testing may also identify
ariants of uncertain significance.” This term indicates that
e nucleotide change is not commonly recognized to be
riable (or polymorphic) in the general population and that
me molecular characteristics of the variant suggest delete-
ous consequences (similar to all pathogenic mutations).
enetic analyses of family members can help establish or
fute the causality of “likely pathogenic” and “variants of
certain significance.” When a variant occurs in multiple
inically affected family members but is absent from clini-
lly unaffected adult family members, the likelihood for
thogenicity increases. In contrast, when a variant occurs in
ultiple clinically unaffected adult family members, the
kelihood for pathogenicity is low.
Adult patients with HCM and an established pathogenic
utation have increased risk for the combined endpoints of
rdiovascular death, nonfatal stroke, or progression to New
ork Heart Association (NYHA) functional class III or IV
mpared with patients with HCM in whom no mutation is
entified (103). Studies suggest that the presence of 1
CM-associated sarcomere mutation is associated with
eater severity of disease (110,111,117,118).
When genetic testing reveals a mutation in the index
tient, ascertainment of genetic status in first-degree rela-
ves can be predictive of risk for developing HCM (105).
enetic counseling should precede genetic testing of family
embers (101). Relatives with overt HCM will have the same
thogenic HCM mutation as the index patient. Pathogenic
utations may also be identified in other relatives with
known clinical status. These mutation carriers should be
aluated by physical examination, electrocardiography, and
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ese individuals should undergo risk stratification (Section
3.1). Mutation carriers without evidence of HCM (genotype
sitive/phenotype negative) are at considerable risk for
ture development of HCM, and guidelines to evaluate these
dividuals are discussed below (13,14). Mutation-negative
mily members and their descendents have no risk for
veloping HCM and do not need further evaluation. Infor-
ation from genotyping may help define clinical manifesta-
ons and outcomes in specific families with HCM (94–96,
5,107–109,119).
When genetic testing is not performed or a mutation is not
entified in the index patient, clinical screening of all
rst-degree family members is important to identify those
ith unrecognized HCM. Offspring of unaffected individuals
not warrant clinical screening unless prompted by unex-
cted signs or symptoms. For more information on screening
tervals, see Section 5.3.1.
1.1. Genotype-Positive/Phenotype-Negative Patients—
ecommendation
ASS I
In individuals with pathogenic mutations who do not express
the HCM phenotype, it is recommended to perform serial
electrocardiogram (ECG), TTE, and clinical assessment at
periodic intervals (12 to 18 months in children and adoles-
cents and about every 5 years in adults), based on the
patient’s age and change in clinical status (16,120–122).
(Level of Evidence: B)
Genetic screening of first-degree relatives of an index
tient with HCM can reveal typically young family mem-
rs with a mutation (genotype positive) but without cardiac
pertrophy (phenotype negative) (Table 3) (13,14,17,105,
3,124). As the clinical expression of HCM usually in-
eases with age, clinical screening (by physical examina-
on, electrocardiography, and 2-dimensional echocardiog-
phy or CMR) of genotype-positive/phenotype-negative
dividuals is also recommended at the intervals indicated
low. Electrocardiographic abnormalities, increased ejec-
on fraction (EF), and delayed myocardial relaxation can
ecede the onset of hypertrophy (17,124). When abnor-
al, these parameters can indicate early emergence of
inical disease. Information about risk of SCD is limited
3,14,121,122).
When family history indicates a high risk for SCD,
riodic assessment of arrhythmias (by exercise stress testing
Holter monitoring) in genotype-positive/phenotype-
gative individuals may be appropriate. Decisions about
rticipation in competitive athletics must be resolved on a
se-by-case basis with the patient and family fully informed
out the potential risks (13) (Section 6.3.3).
.2. Electrocardiography—Recommendations
ASS I
A 12-lead ECG is recommended in the initial evaluation of
patients with HCM. (Level of Evidence: C)
Twenty-four–hour ambulatory (Holter) electrocardiographic moni-
toring is recommended in the initial evaluation of patients with idHCM to detect ventricular tachycardia (VT) and identify patients
who may be candidates for ICD therapy (10,127–129). (Level of
Evidence: B)
Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring or event recording is recommended in patients with
HCM who develop palpitations or lightheadedness (10,127,128).
(Level of Evidence: B)
A repeat ECG is recommended for patients with HCM when
there is worsening of symptoms. (Level of Evidence: C)
A 12-lead ECG is recommended every 12 to 18 months as a
component of the screening algorithm for adolescent first-
degree relatives of patients with HCM who have no evidence of
hypertrophy on echocardiography. (Level of Evidence: C)
A 12-lead ECG is recommended as a component of the screen-
ing algorithm for first-degree relatives of patients with HCM.
(Level of Evidence: C)
ASS IIa
Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring, repeated every 1 to 2 years, is reasonable in
patients with HCM who have no previous evidence of VT to
identify patients who may be candidates for ICD therapy (129).
(Level of Evidence: C)
Annual 12-lead ECGs are reasonable in patients with known HCM
who are clinically stable to evaluate for asymptomatic changes in
conduction or rhythm (i.e., AF). (Level of Evidence: C)
ASS IIb
Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring might be considered in adults with HCM to assess
for asymptomatic paroxysmal AF/atrial flutter. (Level of Evi-
dence: C)
he 12-lead ECG is useful largely for raising the suspicion of
CM in family members without LV hypertrophy and in
ble 3. Proposed Clinical Screening Strategies With
hocardiography (and 12-Lead ECG) for Detection of
ypertrophic Cardiomyopathy With Left Ventricular Hypertrophy
Families*
e 12 y
Optional unless
Malignant family history of premature death from HCM or other
adverse complications
Patient is a competitive athlete in an intense training program
Onset of symptoms
Other clinical suspicion of early LV hypertrophy
e 12 to 18–21 y†
Every 12–18 mo
e 18–21 y
At onset of symptoms or at least every 5 y. More frequent intervals are
appropriate in families with a malignant clinical course or late-onset HCM.
*When pathologic mutations are not identified or genetic testing is either
biguous or not performed.
†Age range takes into consideration individual variability in achieving
ysical maturity and in some patients may justify screening at an earlier age.
itial evaluation should occur no later than early pubescence (125).
ECG indicates electrocardiogram; HCM, hypertrophic cardiomyopathy; and
, left ventricular.
Adapted with permission from Maron et al. (126).entifying patterns such as Wolff-Parkinson-White syn-
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,130–132). In addition, patterns mimicking myocardial
farction may provide evidence of the diagnosis and may be
esent in young individuals before there is manifest evidence
wall thickening on echocardiography (10,132,133). The
-lead ECG is abnormal in 75% to 95% of patients with
CM (9,131,132). These abnormalities do not correlate with
verity or pattern of hypertrophy as determined by echocar-
ography.
Ambulatory electrocardiographic monitoring for detection
ventricular tachyarrhythmias plays an important role in
sk stratification of asymptomatic or symptomatic patients
ith HCM because episodes of nonsustained ventricular
chycardia (NSVT) identify patients at significantly higher
sk of subsequent SCD (9,10,132–134). It is reasonable to
rform serial ambulatory electrocardiographic monitoring
an annual basis or every 2 years in patients who are stable
d do not manifest arrhythmias on baseline 12-lead ECG
d Holter monitoring and who do not have ICDs.
The yield of ambulatory electrocardiographic monitoring
r detection of AF or atrial flutter in patients who were
eviously asymptomatic without arrhythmias is unknown.
.3. Imaging
.3.1. Echocardiography—Recommendations
ASS I
A TTE is recommended in the initial evaluation of all patients
with suspected HCM (9,20,66,67,135–138). (Level of Evi-
dence: B)
A TTE is recommended as a component of the screening
algorithm for family members of patients with HCM unless the
family member is genotype negative in a family with known
definitive mutations (41,126,139,140). (Level of Evidence: B)
Periodic (12 to 18 months) TTE screening is recommended for
children of patients with HCM, starting by age 12 years or
earlier if a growth spurt or signs of puberty are evident and/or
when there are plans for engaging in intense competitive
sports or there is a family history of SCD (126,141). (Level of
Evidence: C)
Repeat TTE is recommended for the evaluation of patients with
HCM with a change in clinical status or new cardiovascular
event (39,45,57,142–145). (Level of Evidence: B)
A transesophageal echocardiogram (TEE) is recommended for
the intraoperative guidance of surgical myectomy (146–148).
(Level of Evidence: B)
TTE or TEE with intracoronary contrast injection of the candi-
date’s septal perforator(s) is recommended for the intraproce-
dural guidance of alcohol septal ablation (62,149–151). (Level
of Evidence: B)
TTE should be used to evaluate the effects of surgical myec-
tomy or alcohol septal ablation for obstructive HCM (61,62,
152–156). (Level of Evidence: C)
ASS IIa
TTE studies performed every 1 to 2 years can be useful in the
serial evaluation of symptomatically stable patients with HCM
to assess the degree of myocardial hypertrophy, dynamic
obstruction, and myocardial function (20,67,136). (Level of
Evidence: C) asExercise TTE can be useful in the detection and quantification
of dynamic LVOT obstruction in the absence of resting outflow
tract obstruction in patients with HCM (8,45,143,145,157).
(Level of Evidence: B)
TEE can be useful if TTE is inconclusive for clinical decision
making about medical therapy and in situations such as
planning for myectomy, exclusion of subaortic membrane or
mitral regurgitation secondary to structural abnormalities of
the mitral valve apparatus, or in assessment for the feasibility
of alcohol septal ablation (146–148). (Level of Evidence: C)
TTE combined with the injection of an intravenous contrast
agent is reasonable if the diagnosis of apical HCM or apical
infarction or severity of hypertrophy is in doubt, particularly
when other imaging modalities such as CMR are not readily
available, not diagnostic, or are contraindicated. (Level of
Evidence: C)
Serial TTE studies are reasonable for clinically unaffected
patients who have a first-degree relative with HCM when
genetic status is unknown. Such follow-up may be considered
every 12 to 18 months for children or adolescents from
high-risk families and every 5 years for adult family members
(41,126,140,141). (Level of Evidence: C)
ASS III: NO BENEFIT
TTE studies should not be performed more frequently than
every 12 months in patients with HCM when it is unlikely that
any changes have occurred that would have an impact on
clinical decision making. (Level of Evidence: C)
Routine TEE and/or contrast echocardiography is not recom-
mended when TTE images are diagnostic of HCM and/or there
is no suspicion of fixed obstruction or intrinsic mitral valve
pathology. (Level of Evidence: C)
Comprehensive TTE and Doppler studies should be per-
rmed in the initial evaluation of all patients with suspected
CM, as well as during follow-up, particularly when there is
change in cardiovascular symptoms or an event. Echocar-
ographic studies are essential for establishing the diagnosis
d the nature and extent of hypertrophy, defining prognosis,
d guiding management (9,20,66,67,135–138). Although
ptal thickness15 mm is commonly used to identify HCM,
e must be aware of the potential confusion with secondary
pertrophy attributable to aortic valve or discrete subaortic
enosis, systemic hypertension, amyloidosis, and other ge-
tic phenocopies such as Fabry disease (158). In affected
mily members with HCM, the degree of hypertrophy may
below the usual diagnostic threshold of 15 mm LV wall
ickness, and indeed, some patients carry an HCM-definitive
utation without hypertrophy.
It has been suggested that identification of morphologic
btypes of LV hypertrophy, namely apical hypertrophy
59) or septal hypertrophy with reverse or neutral curvature,
sigmoid shape (160), has implications for the likelihood of
tection of myofilament mutations and prognosis (139).
owever, there is no recognized relationship between the
ttern or distribution of LV hypertrophy and clinical course
outcome. Nevertheless, documentation of the extent of
pertrophy is important because there is a relatively linear
sociation between maximal wall thickness and sudden
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m (161).
The presence of dynamic LVOT obstruction is related to
mptomatic status, as well as development of AF, embolic
mplications, and death (45,57,142–145). Continuous wave
oppler studies can accurately quantitate the LVOT gradient
d determine the response to pharmacologic (157) and
terventional therapy. Amyl nitrite can be used to provoke
hocardiographically documented gradients when available
d in laboratories with expertise and has the advantage of
ing capable of being integrated into a single examination.
he correlation between pharmacologic and physiologic ex-
cise provocation of outflow gradients is unresolved. Care
ust be taken to correctly identify the site of obstruction,
stinguish the Doppler spectral profile from cavity oblitera-
on, and avoid contamination of the signal by mitral regur-
tation. Although many patients have dynamic LVOT ob-
ruction at rest, a significant number will have new or higher
adients after the Valsalva maneuver, inhalation of amyl
trite, or during provocative exercise (8). In HCM, it is the
ak instantaneous LVOT velocity, usually caused by SAM,
at should be used to determine the maximum gradient,
ing the modified Bernoulli formula (Table 2).
Systolic function, as assessed by wall motion and EF, is
ually normal in patients with HCM; however, the develop-
ent of systolic dysfunction heralds the risk of progressive
d irreversible heart failure, which may result in heart
ansplantation or death (39). The importance of diastolic
sfunction in HCM has led to an extensive search for
ninvasive methods to quantify its severity. With the com-
ex interplay of factors causing diastolic dysfunction in
CM, no single noninvasive measure has been demonstrated
superior (162,163). LA volume may provide a long-term
dication of the effects of chronically elevated filling pres-
res in patients with HCM (164–166). Patients with HCM
d a maximal LA volume index 34 mL/m2 have a higher
cidence of abnormal diastolic filling, a higher mitral inflow/
nular velocity (E/e‘) ratio, a higher calculated LA pressure,
d less favorable outcome (164,166). Moreover, LA volu-
etric remodeling predicts exercise capacity in nonobstruc-
ve HCM and thus may reflect chronic LV diastolic burden
dependent of LVOT obstruction. The more recent use of
yocardial deformation measurements to quantify strain
rameters, torsion, and dyssynchrony has detected abnor-
alities in systolic performance, especially longitudinal
rain and twist (167–171). These methods have also shown
omise in better quantifying abnormalities in early relax-
ion and elevation of filling pressures (172). They may also
useful in distinguishing HCM from other forms of
pertrophy (173), as well as detecting preclinical disease
7,19,174).
Echocardiographic studies are useful in patients with
VOT obstruction who fail to respond to medical therapy and
ho undergo invasive intervention (61,146–148,155,175,
6). TEE studies, performed before arrival in the operating
ite for surgical septal myectomy (and intraoperative TEE),
n determine the length and extent of myectomy required,
aluate the presence and severity of mitral regurgitation
dependent of obstruction, and identify the presence of (8normal papillary muscle architecture (146–148,155,176).
ollowing myectomy, postbypass intraoperative TEE studies
n confirm the adequacy of myectomy and quantitate resid-
l gradients, severity of mitral and aortic regurgitation,
ntricular function, and development of a ventricular septal
fect (146–148,155,176). When the myectomy is inadequate
sed on TEE study, surgical revision can be considered.
Intraprocedural echocardiographic studies should be rou-
nely performed during alcohol septal ablation procedures
2,149–152,156,177). Contrast-enhanced echocardiographic
udies with intracoronary injection of the candidate coronary
ptal perforator(s) are important in determining the perfu-
on bed supplied by the septal perforator so that only an
propriate site and degree of myocardium is infarcted and
mplications avoided (149–151). After alcohol septal abla-
on there may be an early recurrence in the LVOT gradient
few days after the procedure, with subsequent reduction
er 6 to 12 months (152,156).
It should be recognized that in some patients TTE studies
ay be limited by image quality, and other investigations,
cluding CMR, should be performed. In addition, TEE may
tect the presence of subaortic membrane causing fixed
struction with or without coexisting dynamic obstruction.
patients with the apical variant of HCM, the diagnosis is
issed by echocardiographic studies in about 10% of patients
59), and the use of peripheral injection of an echocardio-
aphic contrast agent, as well as CMR, may be useful in
tablishing the diagnosis. Similarly, a subset of patients with
CM may have an apical LV aneurysm associated with
rmal epicardial coronary arteries (159), which is usually
st visualized with CMR. TEE studies may be helpful in
me patients, particularly when the cause and severity of
itral regurgitation are uncertain (147,148).
.3.2. Stress Testing—Recommendations
ASS IIa
Treadmill exercise testing is reasonable to determine func-
tional capacity and response to therapy in patients with HCM.
(Level of Evidence: C)
Treadmill testing with monitoring of an ECG and blood pressure
is reasonable for SCD risk stratification in patients with HCM
(89,90,178). (Level of Evidence: B)
In patients with HCM who do not have a resting peak instan-
taneous gradient of greater than or equal to 50 mm Hg,
exercise echocardiography is reasonable for the detection and
quantification of exercise-induced dynamic LVOT obstruction
(8,88–90). (Level of Evidence: B)
Exercise testing with monitoring of ECG and cuff blood
essure is helpful in risk assessment of patients with
CM, because abnormal blood pressure responses to
ercise (defined as either a failure to increase by at least
mm Hg or a drop of at least 20 mm Hg during effort) has
en demonstrated to be 1 factor associated with risk of
CD (9,10,89,90,134,178). A hypotensive blood pressure
sponse was defined as either an initial increase in systolic
ood pressure with a subsequent fall by peak exercise of
20 mm Hg compared with peak blood pressure value
,90) or a continuous decrease in systolic blood pressure
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red with baseline. A flat response was defined by a
ange in systolic blood pressure during the whole exer-
se period of 20 mm Hg compared with the resting
stolic blood pressure. Most published studies examining
ercise blood pressure response use symptom-limited
eadmill exercise testing with a Bruce protocol (89,178),
hereas others use symptom-limited bicycle ergometry,
ith 25-W increments in 3-minute stages (90).
Combining exercise testing with Doppler echocardiogra-
y is also useful for determining the presence of physiolog-
ally provocable LVOT obstruction and is particularly help-
l in patients with symptoms during routine physical
tivities who do not manifest outflow obstruction at rest (8).
tress testing modalities include either bicycle, treadmill
ing the Bruce protocol, or cardiopulmonary (metabolic)
sting, with measurement of gradient either during or imme-
ately after exercise (8). In symptomatic patients with a peak
sting gradient of 50 mm Hg, it is helpful to perform
ercise echocardiography to determine if a significant
ercise-induced gradient (or increase in mitral regurgitation)
augmentation thereof is present.
The role of metabolic stress testing (i.e., determination of
aximum oxygen consumption) in the routine evaluation of
tients with HCM remains to be decided, particularly with
gard to clinical outcome, but in individual patients this test
ay be helpful in providing a more precise assessment of
nctional capacity (179).
.3.3. Cardiac Magnetic Resonance—
ecommendations
ASS I
CMR imaging is indicated in patients with suspected HCM
when echocardiography is inconclusive for diagnosis (180,181).
(Level of Evidence: B)
CMR imaging is indicated in patients with known HCM when
additional information that may have an impact on manage-
ment or decision making regarding invasive management, such
as magnitude and distribution of hypertrophy or anatomy of the
mitral valve apparatus or papillary muscles, is not adequately
defined with echocardiography (15,180–183). (Level of Evi-
dence: B)
ASS IIa
CMR imaging is reasonable in patients with HCM to define
apical hypertrophy and/or aneurysm if echocardiography is
inconclusive (180,182). (Level of Evidence: B)
ASS IIb
In selected patients with known HCM, when SCD risk stratifi-
cation is inconclusive after documentation of the conventional
risk factors (Section 6.3.1), CMR imaging with assessment of
late gadolinium enhancement (LGE) may be considered in
resolving clinical decision making (184–188). (Level of Evi-
dence: C)
CMR imaging may be considered in patients with LV hypertro-
phy and the suspicion of alternative diagnoses to HCM, includ-
ing cardiac amyloidosis, Fabry disease, and genetic phenocop- laies such as LAMP2 cardiomyopathy (189–191). (Level of
Evidence: C)
here have been significant advances in CMR in recent years,
d most centers now have access to this advanced imaging
chnique. Compared with other noninvasive cardiac imaging
odalities, CMR provides superior spatial resolution with
arp contrast between blood and myocardium, as well as
mplete tomographic imaging of the entire LV myocardium
d therefore the opportunity to more accurately characterize
e presence, distribution, and extent of LV hypertrophy in
CM. Because of the technical complexity of CMR imaging,
ta from the published literature are only generalizable if
aging is performed with high technical quality by experi-
ced operators and interpreted by well-trained and experi-
ced readers.
The primary role for CMR in patients with HCM is
arification of diagnosis and phenotype. Advances in
dimensional echocardiography have demonstrated the het-
ogeneity of the hypertrophic phenotype in patients with
CM, particularly with regard to distribution of LV hyper-
ophy and mechanisms of outflow obstruction (8–10,15,
,72,192). However, there remain patients in whom the
agnosis of HCM is suspected but the echocardiogram is
conclusive, mostly because of suboptimal imaging from
or acoustic windows or when hypertrophy is localized to
gions of the LV myocardium not well visualized by
hocardiography (15). In 1 study, 6% of patients with
spected HCM were identified with increased LV wall
ickness (predominantly in the anterolateral wall) by CMR
t not by echocardiography (15,181,183). In addition, in
tients with HCM in whom hypertrophy is predominantly
nfined to the apex (i.e., apical HCM), increased wall
ickness in this region of the LV myocardium may be
fficult to visualize clearly with echocardiography but can be
ell seen with CMR (180,182). Similarly, in the subgroup of
tients with HCM who develop apical aneurysms, CMR can
ore readily detect the presence of an aneurysm (particularly
hen small) compared with noncontrast echocardiography
82). Identification of the end-stage phenotype and particu-
rly an apical aneurysm has implications for management in
at an ICD may be indicated and anticoagulation could be
nsidered, based on the morphologic appearance of the
eurysm. In addition to diagnosis, the extent of maximal LV
all thickening may be underestimated by echocardiography
mpared with CMR, particularly when this region involves
e anterolateral wall (15,183). This observation is related to
e limitation of 2-dimensional echocardiography in differ-
tiating the epicardial border of the lateral LV free wall from
oracic parenchyma, allowing significant underestimation of
all thickness compared with CMR, which provides more
liable definition of the epicardial border. Accurate charac-
rization of the HCM phenotype by CMR may also be useful
management decisions for invasive therapies (septal my-
tomy or alcohol septal ablation) by more precisely defining
e location and magnitude of hypertrophy, as well as
aracterizing the mitral and submitral apparatus and papil-
ry muscles (193,194).
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entify areas of myocardial fibrosis in patients with HCM
s been the subject of a growing area of the literature
85–187,195,196). The extent and transmural distribution of
eas of infarction can be quantitatively defined in patients
ith CAD (197). Many studies have now documented that
proximately half of patients with HCM have LGE sugges-
ve of areas of fibrosis that in some patients may occupy a
bstantial volume of LV myocardium (i.e., on average, 10%
the LV wall) (185,195). Although patients with the
d-stage phenotype almost universally demonstrate such
ndings (39), patients with HCM with preserved systolic
nction may also have areas of LGE (185–187). Importantly,
tients with HCM with evidence of LGE on CMR imaging
nd to have more markers of risk of SCD, such as NSVT on
olter monitoring, than patients without LGE (184,186).
It is a plausible and attractive concept that areas of LGE
.e., probably largely replacement myocardial fibrosis) could
present a substrate for the generation of malignant ventric-
ar tachyarrhythmias in HCM and thus a marker for risk of
CD. Several studies have addressed this issue and have
ported either trends in such a direction or significant
sociations between the presence of LGE (not extent) and
rdiac outcome events (187,198). However, there is insuffi-
ent evidence at this time to support a significant association
tween the extent of LGE and outcome. Larger studies with
nger follow-up and more events with greater statistical
wer are needed to fully characterize whether the finding of
GE can be considered a specific risk marker for SCD to the
me degree as currently accepted markers such as family
story of SCD or extreme LV wall thickness. Nonetheless,
e present cross-sectional and short-term follow-up data
ould support a potential role of contrast-enhanced CMR
ith evidence of LGE) as an arbitrator to consider in clinical
cision making for primary prevention ICDs in patients in
hom high-risk status for SCD remains uncertain after
sessment of conventional risk factors (185,186).
In some patients with LV hypertrophy, CMR imaging can
pict patterns of LGE that may suggest an alternative
agnosis. In patients with Anderson-Fabry disease, it has
en reported that approximately half have LGE localized to
e mid-myocardial portion of the basal inferolateral wall,
aring the subendocardium (191), a location and distribution
LGE that may help distinguish this disease from other
rms of nonischemic cardiomyopathies such as HCM (189).
atterns of LGE in HCM are heterogeneous, may occur
mmonly in either the ventricular septum or LV free wall,
d usually involve segments of the chamber that are most
pertrophied and do not conform to particular coronary
terial distributions (185).
Among patients with LV hypertrophy caused by cardiac
yloidosis, it has been reported that approximately 70%
monstrate a pattern of global subendocardial gadolinium
hancement, a pattern of enhancement not usually seen in
tients with HCM (190). These data suggest that gadolinium-
hanced CMR imaging may be useful in select cases to
sist a clinician in the differential diagnosis of a patient with
V hypertrophy. H.4. Detection of Concomitant
oronary Disease—Recommendations
ASS I
Coronary arteriography (invasive or computed tomographic
imaging) is indicated in patients with HCM with chest discom-
fort who have an intermediate to high likelihood of CAD when
the identification of concomitant CAD will change manage-
ment strategies. (Level of Evidence: C)
ASS IIa
Assessment of coronary anatomy with computed tomographic
angiography (CTA) is reasonable for patients with HCM with
chest discomfort and a low likelihood of CAD to assess for
possible concomitant CAD. (Level of Evidence: C)
Assessment of ischemia or perfusion abnormalities suggestive
of CAD with single photon emission computed tomography
(SPECT) or positron emission tomography (PET) myocardial
perfusion imaging (MPI; because of excellent negative predic-
tive value) is reasonable in patients with HCM with chest
discomfort and a low likelihood of CAD to rule out possible
concomitant CAD. (Level of Evidence: C)
ASS III: NO BENEFIT
Routine SPECT MPI or stress echocardiography is not indi-
cated for detection of “silent” CAD-related ischemia in patients
with HCM who are asymptomatic. (Level of Evidence: C)
Assessment for the presence of blunted flow reserve (micro-
vascular ischemia) using quantitative myocardial blood flow
measurements by PET is not indicated for the assessment of
prognosis in patients with HCM. (Level of Evidence: C)
Chest discomfort is a common symptom in patients with
CM. A key management issue revolves around whether the
scomfort may be caused by concomitant epicardial obstruc-
ve CAD with inducible ischemia, a consequence of micro-
scular dysfunction, or a combination of these factors (9).
he concomitant presence of CAD, particularly if severe, in
tients with HCM identifies a higher risk for adverse
tcomes and patients who are potential candidates for
vascularization (199,200). Moreover, in considering man-
ement options such as alcohol septal ablation or septal
yectomy for patients with highly symptomatic HCM,
owledge of coronary anatomy is an important factor
forming the decision.
Myocardial bridging (i.e., tunneling) is a clinical feature in
tients with HCM that may be associated with myocardial
chemia in the absence of epicardial coronary stenosis. In
yocardial bridging, a segment of the left anterior descend-
g coronary artery courses within the myocardium. The
evalence of myocardial bridging varies based on the type of
vestigation. In a recent autopsy-based study in patients with
CM, bridging was evident in 40% of hearts (201), whereas
giographic prevalence in HCM is reported to be 15% (202).
yocardial bridges are a frequent component of phenotypi-
lly expressed HCM and more common than in other
sorders with or without LV hypertrophy. Although it has
en suggested that ischemia secondary to bridging could be
potential mechanism for sudden death in patients with
CM (203), there is no consistent evidence to support this
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e possibility that coronary arterial bridges could contrib-
e to increased risk in some individual patients cannot be
cluded, potentially impacting management decisions on
case-by-case basis.
In patients with HCM who have chest pain and who
dergo coronary angiography, the finding of a myocardial
idge raises the question of whether myocardial ischemia
sociated with the bridge is the cause of symptoms. There
e no data assessing stress MPI in patients with HCM with
yocardial bridges; however, reports of patients with myo-
rdial bridges who do not have HCM suggest that stress
rfusion abnormalities may be commonly detected in the
scular territory distal to the bridge (205). Although it has
en suggested that systolic compression of a bridged coro-
ry artery may not be responsible for ischemia because most
ronary blood flow takes place in diastole, angiographic
udies have demonstrated arterial compression in diastole as
ell (206,207).
If chest pain symptoms in a patient with HCM are
spected to be related to abnormal coronary blood flow (as
result of bridging), beta blockers may be effective in
ntrolling the symptoms. Intravenous beta blockade in
tients with myocardial bridges and non-HCM disease has
en shown to have favorable effects on coronary dimensions
d myocardial blood flow and diminished ischemia induced
pacing tachycardia (207). If medical therapy is ineffective,
nsideration can be given to surgery with supra-arterial
yotomy (“unroofing”) (206,208), which may be technically
allenging depending on the depth of the tunneled segment.
TA can define the course and depth of a bridged segment
d may be useful in planning surgical strategy (209).
In patients with HCM who are undergoing surgical myec-
my and in whom preoperative angiography has demon-
rated a myocardial bridge, there are no data to guide the
cision on whether to “unroof” the bridged segment during
e surgical myectomy. In patients with chest pain in whom
rfusion imaging demonstrates blunted flow reserve distal to
e myocardial bridge, supra-arterial myotomy has been
ggested to reduce anginal symptoms.
.4.1. Choice of Imaging Modality
.4.1.1. INVASIVE CORONARY ARTERIOGRAPHY
vasive coronary arteriography is the gold standard for
fining the presence, extent, severity, and location of epi-
rdial coronary stenoses. Performance of invasive coronary
teriography is indicated in patients with HCM when knowl-
ge of these features will importantly influence management
rategies as discussed above. Invasive coronary arteriogra-
y should be a routine accompaniment to an invasive
theterization performed in a patient with HCM for assess-
ent of hemodynamic status and in such cases should
nerally be performed after documentation of hemodynam-
s so as not to influence important measurements such as the
agnitude of the LVOT gradient. When catheterization is
rformed, invasive coronary arteriography should be under-
ken before alcohol septal ablation in order to define the
atomy of the septal perforators in detail and exclude thstructive coronary stenoses. Furthermore, if alcohol septal
lation is being considered, the decision may be influenced
the location and extent of coronary disease as defined by
ronary arteriography.
.4.1.2. NONINVASIVE CTA
lthough there are no published data specifically assessing
e performance characteristics of CTA for documenting the
esence or absence of epicardial CAD in HCM, there is no
ason to believe that performance of the test should differ in
tients with HCM compared with those with suspected or
own CAD. Many studies have reported very good capabil-
y of contemporary CTA technology to distinguish the
esence from absence of a 50% epicardial stenosis (210).
high negative predictive value to exclude CAD is particu-
rly consistent in the literature. In this regard, for patients
ith HCM with chest discomfort, CTA would be a reasonable
rategy to assess for possible concomitant CAD. Anatomical
monstration of an epicardial stenosis does not necessarily
dicate that the symptoms of chest discomfort are attribut-
le to ischemia but are suggestive and outlines a potential
anagement strategy, as well as indicates the need for
ecific preventive strategies.
.4.1.3. SINGLE PHOTON EMISSION COMPUTED
OMOGRAPHY MYOCARDIAL PERFUSION IMAGING
tress SPECT MPI in patients with HCM will often demon-
rate reversible or fixed perfusion defects consistent with
chemia or infarction, respectively, even in the absence of
icardial CAD (211,212). In 1 study, approximately 50% of
ung patients with HCM (unlikely to have CAD attributable
age) had reversible perfusion defects on exercise stress
PECT MPI that were prevented when exercise imaging was
peated on verapamil (213). Several lines of evidence
pport that these defects, even in the absence of symptoms,
present true flow abnormalities and possibly “silent” isch-
ia. Studies of autopsy specimens or myectomy specimens
patients with HCM have shown that patients with HCM
ay have structural abnormalities of the myocardial micro-
sculature (87). During pacing-induced tachycardia, patients
ith HCM with reversible SPECT MPI defects demonstrate
oduction of lactate consistent with ischemia (214), and
llowing relief of outflow tract obstruction with myectomy,
tients with HCM with reversible defects often have normal
rfusion (215).
Fixed defects may also be seen with SPECT MPI, a finding
nsistent with infarction. These patients will often have the
nd-stage” clinical phenotype with reduced EF (211) and
kely correspond to patients who demonstrate LGE in CMR
udies (39).
The concept that true abnormalities of perfusion at the
ssue level may be demonstrated by SPECT MPI in patients
ith HCM in the absence of epicardial CAD, however, does
ake the interpretation of SPECT MPI to detect CAD
allenging. Moreover, myocardial ischemia in patients with
CM, in the absence of epicardial coronary artery stenosis,
ay be attributable to intramural small-vessel abnormalities
massive hypertrophy (216). Given the above discussion,e positive predictive value of an abnormal SPECT MPI
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ith chest discomfort will be relatively low, but the negative
edictive value will be high. The demonstration of a revers-
le defect, even in the absence of CAD, does suggest that the
mptoms of chest discomfort may be caused by ischemia,
though not necessarily related to the presence of obstructive
AD. Although the true performance characteristics of
PECT MPI for detection of CAD have not been rigorously
udied in patients with HCM, it would be expected that the
gative predictive value should be high.
In considering any imaging procedure that involves expo-
re to radiation such as SPECT or PET imaging (Section
4.1.4), CTA (5.4.1.2) or invasive procedures, contemporary
commendations suggest that the potential risks of radiation
posure be taken into account and that the benefits of the
formation gained sufficiently balance those risks (217). This
ncept may be particularly important in patients with HCM,
ho in general will be younger compared with other sub-
oups of patients being evaluated for heart disease.
Interpretation of SPECT perfusion imaging studies in
tients with HCM should be mindful that areas with sub-
antial wall thickening may appear inordinately “hot,” mak-
g other areas without hypertrophy appear to have a rela-
vely mild reduction in tracer activity. Quantitative analysis
ograms may falsely interpret this as a perfusion defect.
oreover, gated SPECT analysis of EF with use of contour-
g programs may underestimate EF, because the assump-
ons driving the contouring algorithms searching for the
docardial borders may not be reliable in some patients with
CM because of the relative brightness of the hypertrophied
all.
.4.1.4. POSITRON EMISSION TOMOGRAPHY
ET imaging has been used in patients with HCM to study
yocardial blood flow as well as myocardial metabolism. In
tients with HCM with normal coronary arteries, myocardial
rfusion PET studies have shown that although resting
yocardial blood flow may be similar to that of normal
ntrol subjects, the augmentation of blood flow with vaso-
lation, for example, dipyridamole, may be significantly
unted (218–221). In addition, such abnormal myocardial
ood flow reserve was shown to be more pronounced in the
bendocardial regions, consistent with so-called “apparent”
ansient ischemic cavity dilatation (212,218,219). In 1 study
ing techniques to quantify myocardial blood flow reserve
ith PET perfusion tracers, patients with HCM who had
unted flow reserve in response to hyperemic stress had
ore unfavorable event-free survival compared with pa-
ents with preserved hyperemic flow reserve (220). A
llow-up study suggested that 1 mechanism for the
favorable outcomes associated with the flow reserve
normalities included progression to a remodeled, end-
age phenotype (221). These findings are consistent with
e concept that repetitive episodes of myocardial ischemia
ay influence long-term outcome of patients with HCM.
owever, the quantitative PET techniques used in these
udies are not part of routine clinical practice, and the
anagement implications of identifying abnormalities in
ow reserve are unresolved. ta.4.1.5. STRESS ECHOCARDIOGRAPHY
here are no published studies addressing the performance
aracteristics of stress echocardiography to detect or exclude
AD in patients with HCM. Although performance of this
odality has been well studied in patients who do not have
CM and criteria about appropriate use of the test exist (222),
pects of the HCM phenotype would in theory undermine
rformance. Patients with HCM have heterogeneous wall-
ickness patterns, and wall motion at rest may appear
normal in regions of hypertrophied myocardium. A wall-
otion response to stress therefore would be complex to
terpret and may be particularly so in the presence of the
hanced loading that occurs in the setting of outflow tract
struction, which may be seen in up to 75% of patients
ring exercise. For these reasons, stress echocardiography to
tect or rule out CAD may be unreliable in HCM but may be
eful to document the presence or magnitude of outflow tract
struction generated by exercise (8) (Section 4.1).
. Management of HCM
reatment of patients with HCM requires a thorough under-
anding of the complex, diverse pathophysiology and natural
story and must be individualized to the patient. The general
proach of the writing committee is outlined in Figure 3.
.1. Asymptomatic Patients—
ecommendations
ASS I
For patients with HCM, it is recommended that comorbidities
that may contribute to cardiovascular disease (e.g., hyperten-
sion, diabetes, hyperlipidemia, obesity) be treated in compli-
ance with relevant existing guidelines (223). (Level of Evi-
dence: C)
ASS IIa
Low-intensity aerobic exercise is reasonable as part of a
healthy lifestyle for patients with HCM (10,224). (Level of
Evidence: C)
ASS IIb
The usefulness of beta blockade and calcium channel blockers
to alter clinical outcome is not well established for the man-
agement of asymptomatic patients with HCM with or without
obstruction (10). (Level of Evidence: C)
ASS III: HARM
Septal reduction therapy should not be performed for asymp-
tomatic adult and pediatric patients with HCM with normal
effort tolerance regardless of the severity of obstruction
(9,10). (Level of Evidence: C)
In patients with HCM with resting or provocable outflow tract
obstruction, regardless of symptom status, pure vasodilators
and high-dose diuretics are potentially harmful (3,9). (Level of
Evidence: C)
A large proportion of patients presenting with HCM are
ymptomatic, and most will achieve a normal life expec-
ncy (48,131,225). It is essential to educate these patients
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December 13/20, 2011:e212–60 ACCF/AHA Hypertrophic Cardiomyopathy Guidelined their families about the disease process, including screen-
g of first-degree relatives and avoiding particularly strenu-
s activity or competitive athletics (134). Risk stratification
r SCD should also be performed in all patients, irrespective
whether symptoms are present (9,10).
Because concomitant CAD has a significant impact on
rvival in patients with HCM (199), it is recommended that
her risk factors that may contribute to atherosclerotic
rdiovascular disease be treated aggressively in concordance
ith existing guidelines (Figure 3) (10,223). This includes
gressive modification of risk factors such as hypertension,
abetes, obesity, and hyperlipidemia (223). A low-intensity
robic exercise program is also reasonable to achieve car-
gure 3. Treatment algorithm. ACE indicates angiotensin-convert
s; EF, ejection fraction; GL, guidelines; HCM, hypertrophic cardioovascular fitness (224). haHydration and avoidance of environmental situations
here vasodilatation may occur are important in the
ymptomatic patient with resting or provocable LVOT
struction. High-dose diuretics and vasodilators (for
eatment of other diseases such as hypertension) should be
oided, because these may exacerbate the degree of
struction (3,9). However, the lack of symptoms attrib-
able to HCM should not detract from the use of negative
otropic agents such as beta blockers or calcium channel
ockers as treatment for relevant comorbidities such as
pertension (10). Although data support the use of
rapamil to relieve symptoms in HCM, other calcium
tagonists such as diltiazem, even though widely used,
yme; ARB, angiotensin receptor blocker; DM, diabetes melli-
thy; HTN, hypertension; and LV, left ventricular.ing enzve not been studied systematically.
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hibitors of the renin-angiotensin pathway or statins or the
lcium channel inhibitor diltiazem (226) may prevent
ogression of hypertrophy in animal models of HCM
27,228). However, there is no completed RCT to indicate
at these drugs are effective in reducing hypertrophy in
mans with HCM. Thus, these drugs should not be given
ith the intent of altering HCM-related clinical outcome
t only for the control of heart failure–related symptoms.
inally, the indication for septal reduction therapy is to
prove symptoms that are not relieved by medical ther-
y and that impair the patient’s quality of life, usually
nsistent with NYHA functional classes III or IV (9,10).
hus, septal reduction therapy with either septal myectomy
alcohol septal ablation should not be performed in the
ymptomatic patient, regardless of the severity of obstruc-
on (9,10).
.2. Symptomatic Patients
.2.1. Pharmacologic Management—
ecommendations
ASS I
Beta-blocking drugs are recommended for the treatment of
symptoms (angina or dyspnea) in adult patients with ob-
structive or nonobstructive HCM but should be used with
caution in patients with sinus bradycardia or severe con-
duction disease (3,9,10,134,137,229–236). (Level of Evi-
dence: B)
If low doses of beta-blocking drugs are ineffective for
controlling symptoms (angina or dyspnea) in patients with
HCM, it is useful to titrate the dose to a resting heart rate of
less than 60 to 65 bpm (up to generally accepted and
recommended maximum doses of these drugs) (3,10,137,
229–236). (Level of Evidence: B)
Verapamil therapy (starting in low doses and titrating up to
480 mg/d) is recommended for the treatment of symptoms
(angina or dyspnea) in patients with obstructive or nonob-
structive HCM who do not respond to beta-blocking drugs or
who have side effects or contraindications to beta-blocking
drugs. However, verapamil should be used with caution in
patients with high gradients, advanced heart failure, or sinus
bradycardia (10,134,137,237–241). (Level of Evidence: B)
Intravenous phenylephrine (or another pure vasoconstricting
agent) is recommended for the treatment of acute hypotension
in patients with obstructive HCM who do not respond to fluid
administration (137,242–244). (Level of Evidence: B)
ASS IIa
It is reasonable to combine disopyramide with a beta-blocking
drug or verapamil in the treatment of symptoms (angina or
dyspnea) in patients with obstructive HCM who do not respond to
beta-blocking drugs or verapamil alone (10,134,137,245–248).
(Level of Evidence: B)
It is reasonable to add oral diuretics in patients with
nonobstructive HCM when dyspnea persists despite the use
of beta blockers or verapamil or their combination (67,134).
(Level of Evidence: C)ASS IIb neBeta-blocking drugs might be useful in the treatment of symp-
toms (angina or dyspnea) in children or adolescents with HCM,
but patients treated with these drugs should be monitored for
side effects, including depression, fatigue, or impaired scho-
lastic performance. (Level of Evidence: C)
It may be reasonable to add oral diuretics with caution to
patients with obstructive HCM when congestive symptoms
persist despite the use of beta blockers or verapamil or their
combination (10,134,137). (Level of Evidence: C)
The usefulness of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers in the treatment of symptoms
(angina or dyspnea) in patients with HCM with preserved
systolic function is not well established, and these drugs
should be used cautiously (if at all) in patients with resting or
provocable LVOT obstruction. (Level of Evidence: C)
In patients with HCM who do not tolerate verapamil or in whom
verapamil is contraindicated, diltiazem may be considered.
(Level of Evidence: C)
ASS III: HARM
Nifedipine or other dihydropyridine calcium channel-blocking
drugs are potentially harmful for treatment of symptoms (an-
gina or dyspnea) in patients with HCM who have resting or
provocable LVOT obstruction. (Level of Evidence: C)
Verapamil is potentially harmful in patients with obstructive
HCM in the setting of systemic hypotension or severe dyspnea
at rest. (Level of Evidence: C)
Digitalis is potentially harmful in the treatment of dyspnea in
patients with HCM and in the absence of AF (3,10,137,
249–251). (Level of Evidence: B)
The use of disopyramide alone without beta blockers or vera-
pamil is potentially harmful in the treatment of symptoms
(angina or dyspnea) in patients with HCM with AF because
disopyramide may enhance atrioventricular conduction and
increase the ventricular rate during episodes of AF
(10,66,134,252–257). (Level of Evidence: B)
Dopamine, dobutamine, norepinephrine, and other intravenous
positive inotropic drugs are potentially harmful for the treat-
ment of acute hypotension in patients with obstructive HCM
(3,82,242–244,258–260). (Level of Evidence: B)
The major goal of pharmacologic therapy in symptomatic
tients with HCM is to alleviate symptoms of exertional
spnea, palpitations, and chest discomfort, which may
flect pathophysiologic mechanisms such as LVOT obstruc-
on, reduced supply of myocardial oxygen, mitral regurgita-
on, and impaired LV diastolic relaxation and compliance
,10,134).
Beta blockers are the mainstay of pharmacologic therapy
d the first-line agents because of their negative inotropic
fects (261) and their ability to attenuate adrenergic-induced
chycardia (Figure 3). These effects improve myocardial
ygen supply-demand relationships and hence reduce myo-
rdial ischemia. The reduction in heart rate also prolongs the
astolic filling period, which may allow for more efficient
activation of myocardial contractile proteins, thereby im-
oving diastolic filling (262,263).
In those patients unable to tolerate beta blockers or those
ith symptoms unresponsive to beta blockers, calcium chan-
l blockers may provide effective symptomatic relief. Vera-
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igure 3) (239,264). Possible mechanisms for symptomatic
provement include negative inotropic and rate-lowering
fects similar to those of beta blockers. However, the effect
verapamil on diastolic dysfunction is controversial
4,265–268). Whether improvement in indices of diastolic
rformance is a direct effect of verapamil or the result of
duction in ischemia is uncertain (213). Diltiazem has also
en shown to improve measures of diastolic performance
69) and to prevent or diminish myocardial ischemia (270).
oth verapamil and diltiazem should be used cautiously in
tients with severe outflow tract obstruction, elevated pul-
onary artery wedge pressure, and low systemic blood
essure, because a decrease in blood pressure with treatment
ay trigger an increase in outflow obstruction and precipitate
lmonary edema. Administration of beta-blocking drugs
ith either verapamil or diltiazem should also be performed
ith caution because of the potential for high-grade atrioven-
icular block. In addition, because of the bradycardic effects
hen both classes of agents are used concomitantly, the
dition of verapamil or diltiazem to a beta blocker may
event titration of the beta blocker to optimal dosage.
ihydropyridine class calcium channel blockers (e.g., nifed-
ine) should not be used in patients with obstructive physi-
ogy because their vasodilatory effects may aggravate out-
ow obstruction.
In patients with obstructive HCM who remain symptom-
ic despite the use of beta blockers and calcium channel
ockers, alone or in combination, disopyramide may be
fective in ameliorating symptoms in many patients (Figure 3)
57,271). Anticholinergic side effects may occur and can be
anaged if necessary by dose reduction. Symptomatic benefit
ith disopyramide appears to represent a pure negative
otropic effect. The initiation of disopyramide should be
rformed in-hospital with cardiac monitoring for potential
rhythmias and lengthening of the QT. Diuretics may be
fective for symptomatic relief in patients with pulmonary
ngestion but should be used judiciously in those with
tflow tract obstruction.
.2.2. Invasive Therapies—Recommendations
ASS I
Septal reduction therapy should be performed only by experi-
enced operators in the context of a comprehensive HCM
clinical program and only for the treatment of eligible patients
with severe drug-refractory symptoms and LVOT obstruction.†
(272) (Level of Evidence: C)
xperienced operators are defined as an individual operator
ith a cumulative case volume of at least 20 procedures or an
dividual operator who is working in a dedicated HCM
ogram with a cumulative total of at least 50 procedures
ection 6.2.2.3).
ligible patients are defined by all of the following:
Clinical: Severe dyspnea or chest pain (usually NYHA
functional classes III or IV) or occasionally other exer-
tional symptoms (such as syncope or near syncope) that
interfere with everyday activity or quality of life despite
optimal medical therapy.Hemodynamic: Dynamic LVOT gradient at rest or with
physiologic provocation 50 mm Hg associated with
septal hypertrophy and SAM of the mitral valve.
Anatomic: Targeted anterior septal thickness sufficient to
perform the procedure safely and effectively in the judg-
ment of the individual operator.
ASS IIa
Consultation with centers experienced in performing both
surgical septal myectomy and alcohol septal ablation is rea-
sonable when discussing treatment options for eligible pa-
tients with HCM with severe drug-refractory symptoms and
LVOT obstruction. (Level of Evidence: C)
Surgical septal myectomy, when performed in experienced cen-
ters, can be beneficial and is the first consideration for the
majority of eligible patients with HCM with severe drug-refractory
symptoms and LVOT obstruction (61,62,155,273–275). (Level of
Evidence: B)
Surgical septal myectomy, when performed at experienced
centers, can be beneficial in symptomatic children with HCM
and severe resting obstruction (>50 mm Hg) for whom stan-
dard medical therapy has failed (276). (Level of Evidence: C)
When surgery is contraindicated or the risk is considered
unacceptable because of serious comorbidities or advanced
age, alcohol septal ablation, when performed in experienced
centers, can be beneficial in eligible adult patients with HCM
with LVOT obstruction and severe drug-refractory symptoms
(usually NYHA functional classes III or IV) (62,153,277–281).
(Level of Evidence: B)
ASS IIb
Alcohol septal ablation, when performed in experienced cen-
ters, may be considered as an alternative to surgical myectomy
for eligible adult patients with HCM with severe drug-refractory
symptoms and LVOT obstruction when, after a balanced and
thorough discussion, the patient expresses a preference for
septal ablation (153,273,278,280,281). (Level of Evidence: B)
The effectiveness of alcohol septal ablation is uncertain in
patients with HCM with marked (i.e., >30 mm) septal hyper-
trophy, and therefore the procedure is generally discouraged in
such patients. (Level of Evidence: C)
ASS III: HARM
Septal reduction therapy should not be done for adult patients
with HCM who are asymptomatic with normal exercise toler-
ance or whose symptoms are controlled or minimized on
optimal medical therapy. (Level of Evidence: C)
Septal reduction therapy should not be done unless performed
as part of a program dedicated to the longitudinal and multi-
disciplinary care of patients with HCM. (Level of Evidence: C)
Mitral valve replacement for relief of LVOT obstruction should
not be performed in patients with HCM in whom septal reduc-
tion therapy is an option. (Level of Evidence: C)
Alcohol septal ablation should not be done in patients with
HCM with concomitant disease that independently warrants
surgical correction (e.g., coronary artery bypass grafting for
CAD, mitral valve repair for ruptured chordae) in whom surgical
myectomy can be performed as part of the operation. (Level of
Evidence: C)
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HCM who are less than 21 years of age and is discouraged in
adults less than 40 years of age if myectomy is a viable option.
(Level of Evidence: C)
e Online Data Supplement 2 for additional data regarding
vasive therapies.
Although the writing committee recognizes that surgical
yectomy and ablation are methodologically very different
proaches and interventions, in this section they are dis-
ssed together because they are the 2 generally accepted
ethods for relief of symptoms in patients with LVOT
struction. Most patients with HCM lead active lifestyles
ith minimal or no symptoms, but some patients incur
gnificant symptoms that interfere with everyday activity or
ality of life (48). For symptoms that are attributable to
VOT obstruction, invasive therapies can be used to improve
ality of life (Figure 3). Surgical approaches have been used
r 5 decades (72,144) so that relief of outflow tract obstruc-
on and symptoms can be achieved with minimal perioper-
ive morbidity or mortality in experienced centers (61,155).
owever, some patients are not optimal surgical candidates
.g., because of comorbidities or advanced age) or have such
strong desire to avoid surgery that alternative therapeutic
terventions have been implemented. Alcohol septal abla-
on, which has been in use for the past 17 years, has become
e leading strategy in these circumstances (282). This
ocedure causes a regional infarction of the basal septum,
ereby initially decreasing contractility and eventually caus-
g thinning (because of scarring) of the basal septum and
nsequent widening of the outflow tract.
Dual-chamber pacing has also been used and studied for
e relief of outflow tract obstruction. The proposed mecha-
sm relates to a change in the activation sequence of the
ptum and possibly long-term remodeling. RCTs suggested
modest benefit of pacing therapy, primarily in those 65
ars of age (283,284). In the current era, application of
al-chamber pacing for the relief of symptoms attributable
outflow tract obstruction is primarily used in patients with
gnificant comorbidities for whom both surgical septal my-
tomy and alcohol septal ablation are considered to have
acceptable risk or in patients who already have an im-
anted dual-chamber pacing device (often implanted for
nhemodynamic indications).
.2.2.1. SELECTION OF PATIENTS
is well recognized that the appropriate selection of patients
r individual procedures is an important predictor of out-
me. Because the majority of patients with HCM can
hieve control of their symptoms with optimal pharmaco-
gic therapy, and in light of the complications inherent with
vasive therapies, a core set of clinical, anatomic, and
modynamic criteria are required before patients are con-
dered candidates for invasive therapies. Specifically, pa-
ents must have symptoms attributable to LVOT obstruction
at are refractory to optimal pharmacologic therapy. Simi-
rly, it must be demonstrated that the obstruction is caused
apposition of the mitral valve with the hypertrophied
ptum (and not attributable to systolic cavity obliteration)2,144). It has been generally accepted that maximal instan-
neous gradients of at least 50 mm Hg at rest or with
ysiologic provocation are necessary to produce symptoms
enable to invasive therapies (10).
Given the duration of experience, documented long-term
sults, and safety data, surgical septal myectomy is consid-
ed the preferred treatment for most patients who meet these
iteria (Figure 3). Considerations that would favor surgical
tervention include younger age, greater septal thickness,
d concomitant cardiac disease independently requiring
rgical correction (e.g., intrinsic mitral valve disease or
ronary artery bypass grafting). Additionally, specific ab-
rmalities of the mitral valve and its support apparatus can
ntribute significantly to the generation of outflow tract
struction, suggesting the potential value of additional
rgical approaches (e.g., plication, valvuloplasty, and papil-
ry muscle relocation) and making myectomy more appro-
riate than alcohol septal ablation in some patients
6,80,285–290). Among patients who meet the core selec-
on criteria, factors that influence a decision to proceed with
cohol septal ablation include older or advanced age, signif-
ant comorbidity that selectively increases surgical risk,
.g., significant concerns about lung or airway management)
d the patient’s strong desire to avoid open-heart surgery
ter a thorough discussion of both options.
.2.2.2. RESULTS OF INVASIVE THERAPY FOR THE
ELIEF OF LVOT OBSTRUCTION
ore detailed discussions specific to each type of procedure
llow in subsequent sections of this document. Overall,
ports suggest that technical success, variably defined, is
hieved in 90% to 95% of patients who undergo surgical
yectomy (291), less in septal ablation, and only in the
inority of patients studied in trials of pacemaker therapy
92–295). Patients undergoing septal ablation may have
modynamic and symptomatic improvement comparable to
ptal myectomy if the area of the SAM-septal contact can be
cessed by the first septal perforator and ablated. However,
mpared with septal myectomy in which the hypertrophied
uscle is directly visualized and resected, successful septal
lation is dependent on the variable septal artery anatomy,
hich may not supply the targeted area of the septum in up to
% to 25% of patients (62,296).
In a nonrandomized retrospective evaluation of patients with
CM 65 years of age, survival free from recurrent symptoms
vored myectomy over ablation (89% versus 71%; p0.01)
2). Procedural success is associated with very low procedural
ortality (1% for myectomy [61,155,297], ranging from 0%
4% for ablation) (298–300), and low nonfatal complication
tes (2% to 3% in experienced centers). The exception is
gh-grade atrioventricular block requiring permanent pacemak-
s following septal ablation (in 10% to 20% of patients), an
herent aspect of the septal infarction (301–303). The data from
ials of dual-chamber pacing suggest that there was a sig-
ficant placebo effect and inconsistent symptomatic benefit
83,284,294).
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perator and institutional experience, including procedural
lume, is a key determinant of successful outcomes and
wer complication rates for any procedure. For HCM, a
sease of substantial heterogeneity that is relatively uncom-
on in general cardiology practice, this is an important issue.
s with the recommendations made in the “2008 Focused
pdate Incorporated Into the ACCF/AHA Guidelines for the
anagement of Patients With Valvular Heart Disease” about
pected outcomes for surgeons offering mitral valve repair
04), it would be prudent and appropriate for individual
nters, surgeons, and interventional cardiologists to demon-
rate sufficient success and safety to justify ongoing use of
ese procedures. Although it is difficult to define a precise
se volume or cumulative experience required to perform
ese procedures, at least 1 study suggests that the learning
rve relative to invasive therapy in HCM may require the
rformance of at least 40 procedures (272). As a consensus
inion, the writing committee recommends an operator
lume of at least 20 procedures or that the operator work
ithin the context of an HCM program with a cumulative
ocedural volume of at least 50 procedures. In addition,
ven the data available from experienced centers, operators
d institutions should aim to achieve mortality rates of1%
d major complication rates of 3%, with documented
ccess in both hemodynamic and symptom benefit for their
tients. This is best achieved in the context of a systematic
ogram dedicated to the multidisciplinary and longitudinal
re of patients with HCM.
.2.2.4. SURGICAL THERAPY
ransaortic septal myectomy is currently considered the most
propriate treatment for the majority of patients with ob-
ructive HCM and severe symptoms unresponsive to medical
erapy (Figure 3) (276,291,305–313). Surgical results, al-
ough vastly improved in recent years, are nevertheless
mited to relatively few centers with extensive experience
d particular interest in the management of HCM (288,314).
oth the traditional myectomy (Morrow procedure) with
out a 3-cm long resection (309) or extended myectomy (a
section of about 7 cm) are currently used (288,314).
The transaortic approach remains the primary method of
posure. Virtual abolition of the LV outflow gradient and
itral regurgitation is usually accomplished by muscular
section resulting in physical enlargement of the outflow
act and by interruption of the mitral valve SAM, which is
ually responsible for the outflow gradient (315). Septal
yectomy in the current era is commonly referred to as an
xtended myectomy.” This refers to the fact that the mus-
lar resection becomes progressively wider as the resection
oceeds into the ventricle (i.e., toward the apex), effectively
aking the trough wider at the mid-ventricular level. As a
sult, the myectomy resection is opposite the lateral portion
the anterior leaflet (to avoid conduction tissue), the
ordae, and both papillary muscles. In addition, muscular
section is also performed along the left lateral free wall
lso part of the LVOT), resulting in a much more extensive
yectomy than that originally described by Morrow et al.
out 50 years ago (309). toThe transaortic approach remains the primary method of
posure. Virtual abolition of the LV outflow gradient and
itral regurgitation is usually accomplished by muscular
section resulting in physical enlargement of the outflow
act and by interruption of the mitral valve SAM, which is
ually responsible for the outflow gradient (315). In selected
rcumstances, some surgeons have also used concomitant
itral valve repair, particularly when the anterior leaflet is
ongated. This valve repair maneuver usually involves short-
ing the height of the anterior leaflet. However, residual
itral valve regurgitation after adequate septal myectomy is
most always caused by intrinsic mitral valve abnormalities
ch as ruptured chordae, myxomatous degeneration with
olapse, or annular dilatation, and can be corrected by direct
lve repair. Finally, enlarged or malpositioned papillary
uscles can also contribute to residual obstruction. This can
effectively treated by shaving the hypertrophied papillary
uscles, incising papillary muscles off the ventricular free
all, and in selected circumstances repositioning one papil-
ry muscle by suture approximation to the adjacent papillary
uscle.
The surgical specimen obtained at the time of myectomy
ould be submitted for pathologic examination, not only to
nfirm the histopathology of HCM, but also for special
ains to rule out storage diseases that can mimic HCM (31).
.2.2.4.1. Selection of Patients. It is important to under-
ore that the subjective assessment of operative risk by
inicians frequently results in an overestimate of risk, result-
g in the denial of proven therapies for eligible patients in
vor of less effective or less proven options (316). In patients
rceived to be at prohibitively high risk because of major
morbidities, including age, the use of objective risk tools in
e context of individual institutional experience could lead to
reassessment of operative risk that is lower than initially
ought.
.2.2.4.2. Outcomes. Early Results. Based on the expe-
ence and data assembled from multiple centers worldwide
er the last 4 decades (276,291,305,307,308,310,311), septal
yectomy is established as the most effective and proven
proach for reversing the consequences of heart failure by
oviding amelioration of obstruction (and relief of mitral
gurgitation) at rest, with restoration of functional capacity
d acceptable quality of life at any age, exceeding that
hievable with long-term administration of cardioactive
ugs (10,175). These salutary benefits have been demon-
rated subjectively by patient history and objectively by
creased treadmill time, maximum workload, peak oxygen
nsumption, and improved myocardial oxygen demand,
etabolism, and coronary flow (10,273,294).
LV outflow gradient reduction with myectomy results from
sal septal thinning with resultant enlargement of the LVOT
ea (and redirection of forward flow with loss of the drag and
enturi effects on the mitral valve) (317) and consequently
olition of SAM and mitral-septal contact (314,318,319).
itral regurgitation is also usually eliminated without the
ed for additional mitral valve surgery (148). With myec-
my, LA size (and possibly long-term risk for AF) is reduced
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0,61,148,317,320). Thus, obstructive HCM is a surgically
d mechanically reversible form of heart failure. In experi-
ced centers, operative risk is now particularly low, in the
nge of 1% (175).
Late Results. Relief of outflow obstruction by septal
yectomy may also extend the longevity of patients with
CM (61). Although RCTs involving myectomy surgery
ve not been performed, in a nonrandomized study, myec-
my resulted in excellent long-term survival similar to that in
e general population. After septal myectomy, long-term
tuarial survival was 99%, 98%, and 95% at 1, 5, and 10
ars, respectively (when considering HCM-related mortal-
y). This survival rate did not differ from that expected in a
atched general US population and was superior to that
hieved by patients with obstructed HCM who did not
dergo surgical myectomy (61). Similarly, the rate of SCD
appropriate ICD discharge after myectomy is very low
0.9%) (61,321,322). Nonetheless, surgical myectomy does
t eliminate the need to assess each patient’s risk for SCD
d to consider placement of an ICD in those with a
gnificant risk burden.
.2.2.4.3. Complications. Complications following my-
tomy are rare when performed in experienced centers
15). The risk of complete heart block is approximately 2%
ith myectomy (higher in patients with preexisting right
ndle-branch block), but in myectomy patients who have
d previous alcohol septal ablation, risk is much higher
0% to 85%) (323). Iatrogenic ventricular septal defect
curs in 1% of patients. Finally, the risk of aortic valve or
itral valve injury is also low (1%), particularly when
yectomy is performed by an experienced operator.
.2.2.4.4. Mitral Valve Abnormalities and Other
natomic Issues. Abnormalities of the mitral valve and
bvalvar apparatus (including anomalous direct anterolateral
pillary muscle insertion into anterior mitral leaflet and
ongated mitral leaflets) (80,324) can be identified preoper-
ively with TTE or intraoperative TEE and can be corrected
ith modified mitral valve repair or extended myectomy
chniques without the need for mitral valve replacement.
deed, the excellent early and late outcomes of extended
yectomy for treatment of obstructive HCM have made
itral valve replacement exceedingly rare (315). Associated
generative mitral valve disease (i.e., prolapse, ruptured
ordae) can be treated by concomitant mitral valve repair at
e time of myectomy. Mitral valve repair techniques may
ed to be modified in HCM to avoid subsequent develop-
ent of SAM (325).
Mitral valve replacement in patients with obstruction has
en performed rarely when septal reduction therapy was
dged unsafe or likely to be ineffective. When the basal
ptum is only mildly hypertrophied (16 mm), the risk for
ther iatrogenic ventricular septal defect from excessive
uscular resection or residual postoperative outflow obstruc-
on from inadequate resection increases. Mitral valve re-
acement may be an option in rare patients (326,327). th.2.2.5. ALCOHOL SEPTAL ABLATION
irst reported in 1995 (282), alcohol septal ablation uses
anscoronary administration of absolute ethanol via a percu-
neous approach to induce a localized infarction of the basal
ptum at the point of contact of the anterior mitral valve
aflet, thereby reducing outflow tract gradient and associated
itral regurgitation and simulating the results of surgical
yectomy. Developed as an alternative to surgical septal
yectomy, the technique is particularly useful when surgery
contraindicated and in patients who are considered poor
rgical candidates (279). Since its development, alcohol
ptal ablation has been performed successfully in a large
mber of patients (153).
After measurement of resting or provoked outflow tract
adients, a temporary pacemaker is placed in the right
ntricle because of the risk of procedural complete heart
ock (328–330). With the use of standard angioplasty
uipment and anticoagulation, a guidewire and coronary
gioplasty balloon are placed in the septal perforator that
pears to perfuse the target myocardium. Contrast angiog-
phy of the septal perforator through the balloon central
men with simultaneous echocardiographic guidance
31,332) confirms delivery to only the target myocardium.
bout 1 to 3 mL of alcohol is infused in controlled fashion
51,333–335). Incorporation of myocardial contrast echo-
rdiography reduces the number of septal branches into
hich ethanol is injected and may both improve the success
te and lower cardiac biomarker release and the need for
cing (331–333,336). It is important that the balloon be
flated and that a contrast injection also show that there is no
travasation of dye into the distal left anterior descending
ronary artery. Contrast enhancement of other regions (pap-
lary muscles, free wall) indicates collateral circulation from
e septal perforator artery, and alcohol should not be infused.
decrease in resting and provocable gradients usually occurs
mediately after the procedure (because of stunning), and
modeling can result in continued or variable gradient
duction over the first 3 months after the procedure. Patients
e monitored for arrhythmias and conduction disturbances in
e intensive care unit for 24 to 48 hours; implantation of a
rmanent pacemaker may be necessary for complete or
gh-grade atrioventricular block and through discharge at 3
4 days.
.2.2.5.1. Selection of Patients. Alcohol septal ablation
s the potential for greater patient satisfaction because of the
sence of a surgical incision and general anesthesia, less
erall discomfort, and a much shorter recovery time. The
nefit of alcohol septal ablation in patients of advanced age
similar to that in other patients (277,337). Because the
stoperative risks and complications of cardiac surgery
crease with age, ablation may offer a selective advantage in
der patients, in whom operative risk may be increased
cause of comorbidities. Alcohol septal ablation is not
dicated in children.
On the other hand, longer-term follow-up data are available
r septal myectomy than for septal ablation, a consideration
levant to the selection of patients for either septal reduction
erapy. The likelihood of implantation of a permanent pace-
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yectomy. Clinical and hemodynamic benefit is achieved im-
ediately after recovery from septal myectomy but may be
layed for up to 3 months after septal ablation, although many
tients achieve a notable symptomatic benefit after the proce-
re. Furthermore, patients with massive septal thickness ap-
oaching or exceeding 30 mm may experience little or no
nefit from septal ablation. The surgeon can tailor the myec-
my under direct visualization to address specific anatomic
normalities of the LVOT or mitral valve apparatus, whereas
cohol septal ablation indirectly (and is restricted to) targets the
stribution of the septal perforator artery.
Septal myectomy is the preferred treatment option for most
verely symptomatic patients with obstructive HCM, espe-
ally in younger, healthy adults, whereas septal ablation is
eferred in patients for whom surgery is contraindicated or
nsidered high risk (particularly the elderly) (Figure 3). Data
mparing alcohol septal ablation with septal myectomy are
adequate to fully inform clinical decision making in certain
ses. For such patients, the principle of patient autonomy
ctates that it is appropriate for the informed patient to
oose between the 2 procedures.
.2.2.5.2. Results. Necrosis of the basal ventricular sep-
m (338) produces an immediate fall in gradient from
ecreased septal contraction in 90% of patients
56,300,339–341). This effect is followed by LV remodel-
g over 6 to 12 months, a process that includes scar
traction and resultant widening of the outflow tract, asso-
ated with further reduction in gradient and degree of mitral
gurgitation, regression of hypertrophy, and improvement in
astolic function (154,300,342–344). LA pressure is re-
ced, which may promote a decreased incidence of AF and
elioration of pulmonary hypertension (345). Two studies
ve demonstrated that, as with septal myectomy, the benefit
septal ablation in patients with provocable gradients is
milar to that in patients with resting gradients (346,347).
he beneficial results of alcohol septal ablation have been
ported to almost 5 years after the procedure with improved
nctional and angina classes, exercise capacity, and quality
life (153,300,348–351). However, hemodynamic and
mptomatic success is dependent on the ability to cannulate
d ablate a septal perforator artery that supplies the area of
e SAM-septal contact.
Although RCTs comparing surgical myectomy with alco-
l septal ablation have not been conducted and are highly
likely in the future, meta-analyses have noted similar hemo-
namic and functional improvement over 3 to 5 years when
amining the cumulative average of outcomes (352–354).
hat the meta-analyses do not report are a subset of patients in
hom alcohol septal ablation is unreliable because of the
ability to ablate the area of the SAM-septal contact (355).
lder patients, especially those considered to be at high surgical
sk, may be well served by alcohol septal ablation, whereas
unger patients may benefit most from surgical myectomy
2,279). Despite age differences in treatment allocation, with
ptal ablation patients on average approximately 10 years older
clinical practice (352,353), the 4-year survival rate is similarr the 2 procedures (62,278). Most studies that have compared exrgical myectomy and alcohol septal ablation have involved a
rge single-center experience in which treatment assignment
as not randomized.
.2.2.5.3. Complications. In approximately half of pa-
ents undergoing alcohol septal ablation, temporary complete
rioventricular block occurs during the procedure (328–
0). Persistent complete heart block prompting implantation
a permanent pacemaker occurs in 10% to 20% of patients
sed on the available data (36). Approximately 5% of
tients have sustained ventricular tachyarrhythmias during
spitalization. The in-hospital mortality rate is up to 2%
2,153,279,353). Because of the potential for creating a
ntricular septal defect, septal ablation should not be per-
rmed if the target septal thickness is 15 mm.
Alcohol septal ablation is a therapeutic alternative to
rgical myectomy for selected patients and produces a
ansmural infarction of ventricular septum occupying on
erage 10% of the overall LV wall (53,296,356). There
s been concern that the potential ventricular arrhythmo-
nicity of the scar created by septal ablation might
gment risk in the HCM population. Several studies have
cumented the occurrence of sustained ventricular ar-
ythmias (332,349,357–363) and SCD following septal
lation (322) in about 3% to 10% of patients both with or
ithout risk factors for SCD. In a single-center experience
91), 21% of patients experienced sudden or other
rdiac death, aborted SCD, and/or appropriate ICD dis-
arge resulting in an annualized event rate of 4.4% per
ar after ablation (322). In a second single-center expe-
ence (n89), no mortality was attributable to SCD in
02.3 years of follow-up. However, in a selected subset
42 patients with an ICD or permanent pacemaker that
abled detection of device-stored electrograms, the annu-
ized event rate (VT, ventricular fibrillation, and/or ap-
opriate ICD discharge, including periprocedural arrhyth-
ias) was 4.9% per year (362). Data from another center
ggest appropriate ICD intervention rates after ablation of
8% per year (364); similarly, the multicenter HCM ICD
gistry (n506) demonstrated that the rate of appropriate
D therapy among ablation patients with primary preven-
on ICDs was 3 to 4 times more frequent than in other
tients in that registry (10.3% per year compared with
6% per year) (55). Patients with HCM considered to carry
fficient risk to warrant ICD placement have an annual
cidence of appropriate interventions for VT/ventricular
brillation of 3% to 10% (55,360,364). It is uncertain how
mmon such events are attributable to the procedure or
ternatively to the underlying disease, but the incidence of
stained ventricular arrhythmias after myectomy is ex-
emely low (0.2% to 0.9% per year) (61,321,322).
Meta-analyses have indicated no difference between septal
lation and myectomy in the medium-term incidence of
CD or all-cause mortality (352,365). Although no definitive
idence is available that the ablation scar as such increases
r does not increase) long-term risk for SCD in absolute
rms in this patient population, resolution will require greatly
tended follow-up studies in larger patient cohorts (53,357).
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ASS IIa
In patients with HCM who have had a dual-chamber device
implanted for non-HCM indications, it is reasonable to consider a
trial of dual-chamber atrial-ventricular pacing (from the right
ventricular apex) for the relief of symptoms attributable to LVOT
obstruction (292,294,295,366). (Level of Evidence: B)
ASS IIb
Permanent pacing may be considered in medically refractory
symptomatic patients with obstructive HCM who are subop-
timal candidates for septal reduction therapy (283,292,294,
295,366). (Level of Evidence: B)
ASS III: NO BENEFIT
Permanent pacemaker implantation for the purpose of reducing
gradient should not be performed in patients with HCM who are
asymptomatic or whose symptoms are medically controlled
(283,284,367). (Level of Evidence: C)
Permanent pacemaker implantation should not be performed
as a first-line therapy to relieve symptoms in medically refrac-
tory symptomatic patients with HCM and LVOT obstruction
who are candidates for septal reduction (283,284,367). (Level
of Evidence: B)
e Online Data Supplement 3 for additional data regarding
cing.
Implantation of a dual-chamber pacemaker was proposed as
alternative treatment for patients with severe symptomatic
structive HCM (369–371). Pacing the right ventricular apex
ith maintenance of atrioventricular synchrony results in a
crease in the LVOT gradient and improvement of symptoms
a subset of patients. Although the exact mechanism of
provement with pacing remains unknown, the decrease in
adient may be caused by timing of septal contraction but may
so reflect long-term remodeling (369). Although there was an
itial enthusiasm for dual-chamber pacing as a primary treat-
ent for patients with obstructive HCM, subsequent RCTs
monstrated long-lasting beneficial results in only a small
inority of patients, whereas most perceived improvement was
dged to be a placebo effect (283,284,367). A trial of dual-
amber pacing may be considered for symptomatic patients
ith obstruction in whom an ICD has already been implanted for
gh-risk status.
.2.2.6.1. Results of DDD Pacing. Initial cohort studies
the results of dual-chamber pacing in patients with ob-
ructive HCM and limiting symptoms showed symptomatic
provement in almost 90% of patients, accompanied by an
provement in exercise time and a reduction in gradient
68–371). However, there have been 3 randomized cross-
er trials in which patients received 2 to 3 months of
ntinuous DDD pacing but also underwent a back-up AAI
ode (no pacing) as a control arm (283,284,367). DDD
cing consists of continuously sensing or pacing the atrium
d pacing the right ventricular apex. The overall reduction in
tflow tract gradient was modest (25% to 40%) with fabstantial variation among individual patients. Objective
easurements of exercise capacity were improved during
DD pacing versus baseline, but there was no significant
fference comparing the AAI back-up mode with continuous
DD pacing. Although symptomatic improvement was re-
rted by the majority of patients following continuous DDD
cing, a similar frequency of improvement was reported by
tients during the AAI mode (control mode without pacing).
hese findings suggest a placebo effect as well as a “training
fect” contributing to the initial symptomatic improvement
patients undergoing dual-chamber pacing (283,284,372).
Overall, the percentage of patients with sustained symptom-
ic improvement from continuous dual-chamber pacing varies
om 30% to 80% (292,294,295,366). A consistent improvement
symptoms with a decrease in gradient and objective improve-
ent in exercise duration is seen in 50% of patients. The
erall success rate in terms of symptom relief and gradient
duction is significantly lower than that seen in patients who
dergo septal myectomy. The mean residual gradient after
ptal myectomy is10 mm Hg compared with a 40 to 50 mm
g gradient after dual-chamber pacing (283,284,295,369).
here is no reliable predictor of success for dual-chamber
cing, including the results of acute hemodynamic studies or
orphologic echocardiographic features (295,367,373). Patients
65 years of age may be a subgroup who achieve the greatest
nefit (283). There are no data that indicate dual-chamber
cing either reduces the risk of SCD in patients with HCM or
ters the underlying progression of disease (283,369). Dual-
amber pacing has not been shown to be beneficial for patients
ith nonobstructive HCM (374).
.2.2.6.2. DDD Pacing: Caveats. A thorough under-
anding of the complex interplay between pacemaker pro-
amming and the hemodynamics of HCM is necessary to
hieve possible beneficial results from this therapy. It is
cessary to optimize the atrioventricular delay because too
ort an interval results in hemodynamic deterioration and
o long an atrioventricular interval without complete preex-
tation of the ventricle results in an inadequate response
75). The position of the pacemaker lead is important,
quiring distal apical capture for optimal hemodynamic
sults (376). Programming of rate-adaptive pacing is also
cessary so that full preexcitation of the ventricle is obtained
ring exercise.
.2.2.6.3. Pacing and ICDs. Patients with HCM are at
creased risk for ventricular tachyarrhythmias and SCD.
omprehensive SCD risk stratification should be performed
all patients with HCM (Section 6.3.1). However, current
CD risk stratification does not identify all patients at risk for
ntricular arrhythmias and SCD (377). An ICD has been
own to be effective at aborting SCD in patients with HCM
5). Consideration of an ICD if a pacing device is indicated
r either rhythm or hemodynamic indications is controver-
al in contrast to the situation in patients with established risk
ctors for SCD.
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ecommendations
ASS I
Patients with nonobstructive HCM who develop systolic dys-
function with an EF less than or equal to 50% should be treated
according to evidence-based medical therapy for adults with
other forms of heart failure with reduced EF, including
angiotensin-converting enzyme inhibitors, angiotensin re-
ceptor blockers, beta blockers, and other indicated drugs
(39,378). (Level of Evidence: B)
Other concomitant causes of systolic dysfunction (such as
CAD) should be considered as potential contributors to systolic
dysfunction in patients with HCM. (Level of Evidence: C)
ASS IIb
ICD therapy may be considered in adult patients with advanced
(as defined by NYHA functional class III or IV heart failure)
nonobstructive HCM, on maximal medical therapy, and EF less
than or equal to 50%, who do not otherwise have an indication
for an ICD (39). (Level of Evidence: C)
For patients with HCM who develop systolic dysfunction, it may
be reasonable to reassess the use of negative inotropic agents
previously indicated, for example, verapamil, diltiazem, or
disopyramide, and to consider discontinuing those therapies.
(Level of Evidence: C)
Although HCM has typically been excluded from RCTs in
art failure, there is no compelling reason to believe that the
iology of reduced EF heart failure differs sufficiently to
squalify many highly effective, evidence-based, guideline-
rected therapies for heart failure with reduced EF (379).
tandard heart failure therapies should be implemented in
tients with HCM when the EF is 50% for patients with
AD (39).
The discovery of reduced EF in the setting of HCM is not
consistent with the known natural history of HCM but is
common (approximately 3%) and should prompt an appropri-
e search for other potential contributing causes of LV dysfunc-
n (39). Those causes should include, but are not limited to,
AD, valvular heart disease, and metabolic disorders.
Patients with HCM were not included in the primary
evention ICD trials for patients with heart failure due to
AD or dilated cardiomyopathy (and reducted EF). Prophy-
tic ICD implantation is nevertheless the generally accepted
inical practice for primary prevention in HCM patients with
stolic dysfunction. Furthermore, despite the absence of
inical trials or observational data, the use of negative
otropic drugs that would otherwise be discouraged in the
tting of conventional heart failure with reduced EF can be
nsidered in patients with HCM.
.2.4. Selection of Patients for
eart Transplantation—Recommendations
ASS I
Patients with advanced heart failure (end stage*) and nonob-
structive HCM not otherwise amenable to other treatment
haracterized by systolic dysfunction (EF 50%), often associated with LV
modeling, including cavity enlargement and wall thinning, and because of diffuse
yocardial scarring. afinterventions, with EF less than or equal to 50% (or occasion-
ally with preserved EF), should be considered for heart trans-
plantation (39,381). (Level of Evidence: B)
Symptomatic children with HCM with restrictive physiology
who are not responsive to or appropriate candidates for other
therapeutic interventions should be considered for heart trans-
plantation (382,383). (Level of Evidence: C)
ASS III: HARM
Heart transplantation should not be performed in mildly symp-
tomatic patients of any age with HCM. (Level of Evidence: C)
general, the indications for heart transplantation include
vanced heart disease, typically with NYHA functional class
I or IV symptoms that are refractory to all other reasonable
terventions. Transplant referral for refractory symptoms
es not absolutely require reduced EF, although this treat-
ent strategy is rarely recommended and performed in the
esence of preserved EF. For patients with HCM, outcome
ter heart transplantation is not different from that of patients
ith other heart diseases (39,384,385).
.3. Prevention of SCD
.3.1. SCD Risk Stratification—Recommendations
ASS I
All patients with HCM should undergo comprehensive SCD risk
stratification at initial evaluation to determine the presence of
the following: (50,53,55,127,128,386–392) (Level of Evi-
dence: B)
a. A personal history for ventricular fibrillation, sustained VT,
or SCD events, including appropriate ICD therapy for ven-
tricular tachyarrhythmias.†
b. A family history for SCD events, including appropriate ICD
therapy for ventricular tachyarrhythmias.†
c. Unexplained syncope.
d. Documented NSVT defined as 3 or more beats at greater
than or equal to 120 bpm on ambulatory (Holter) ECG.
e. Maximal LV wall thickness greater than or equal to 30 mm.
ASS IIa
It is reasonable to assess blood pressure response during
exercise as part of SCD risk stratification in patients with HCM
(89,127,390). (Level of Evidence: B)
SCD risk stratification is reasonable on a periodic basis (every
12 to 24 months) for patients with HCM who have not
undergone ICD implantation but would otherwise be eligible in
the event that risk factors are identified (12 to 24 months).
(Level of Evidence: C)
ASS IIb
The usefulness of the following potential SCD risk modifiers is
unclear but might be considered in selected patients with HCM
for whom risk remains borderline after documentation of con-
ventional risk factors:
a. CMR imaging with LGE (184,188). (Level of Evidence: C)
ppropriate ICD discharge is defined as ICD therapy triggered by VT or
ntricular fibrillation, documented by stored intracardiac electrogram or cycle-
gth data, in conjunction with the patient’s symptoms immediately before and
ter device discharge.
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dence: C)
c. Marked LVOT obstruction (45,127,143,390). (Level of
Evidence: B)
ASS III: HARM
Invasive electrophysiologic testing as routine SCD risk strati-
fication for patients with HCM should not be performed. (Level
of Evidence: C)
e Online Data Supplement 4 for additional data regarding
D risk stratification.
A minority of clinically recognized patients with HCM are
dged to be at increased risk for SCD, with a rate of about
per year (53,55,386–389). ICDs offer the only effective
eans of preventing SCD and prolonging life in patients with
CM (55). Selection of patients who are appropriate for
plantation for primary as opposed to secondary prevention
n be a difficult clinical decision, owing to the individuality
each patient and family, variable definitions for risk
arkers, sparse clinical data, the relative infrequency of both
CM and SCD in most clinical practices, and the cumulative
orbidity of living with an ICD.
.3.1.1. ESTABLISHED RISK MARKERS
3.1.1.1. Prior Personal History of Ventricular Fibrillation,
CD, or Sustained VT. As expected, patients with HCM
ho have experienced SCD or sustained VT represent the
ghest risk for subsequent arrhythmogenic events. The
nualized rate of subsequent events is approximately 10%
r year, although it has been shown that individuals may
ve no recurrent events or may have decades-long arrhythmia-
ee intervals between episodes (55,387–389,393).
.3.1.1.2. Family History of SCD. It has been recog-
zed that SCD events can cluster in families. Notably, some
udies have not demonstrated an independent link between
mily history of SCD and risk for individual patients on
ultivariate analysis (50,390,394), whereas others have sug-
sted that family history is an independent predictor (394).
hese differences may be explained in part by the relative
frequency of events but also likely reflect variability in the
finition of a family history of SCD. Some studies have used
definition of SCD in 2 first-degree relatives (50), whereas
hers have counted a single event (127,390). None of these
udies have rigorously accounted for the total number of
inically apparent patients with HCM in each family, nor
ve they included SCD in more remote relations (e.g.,
usins, uncles, aunts, grandparents).
.3.1.1.3. Syncope. Syncope represents a complex symp-
m with a multifactorial etiology that requires a careful
inical history before it can be considered a potential marker
r SCD (50,392). In one analysis, syncope that was
explained or thought to be consistent with arrhythmia
.e., not neurally mediated) showed a significant indepen-
nt association with SCD only when the events occurred
the recent past (6 months) but not if the syncopalisodes occurred 5 years before the clinical visit (392). fine other large study reports a similar independent asso-
ation between recent unexplained syncope and SCD
27). Another study showed that it was the interaction
tween syncope and family history that was an important
ognostic marker (50).
.3.1.1.4. Nonsustained Ventricular Tachycardia. Al-
ough sustained ventricular arrhythmia is clearly associ-
ed with SCD, the data for NSVT are less robust. Only 1
5 studies showed a univariate association between
SVT on 24-hour ambulatory monitors and SCD (50,128,
9,395–397), whereas 1 contemporary and larger study
owed that NSVT is independently associated with SCD
multivariate analysis (127) and is more important in
unger patients (30 years of age) (129). Furthermore,
ercise-induced NSVT has been found to have indepen-
nt association with SCD (398). NSVT probably should
t be considered in a simply binary manner (i.e., as either
sitive or negative), and there may be some value in
ng-term ambulatory monitoring when NSVT is discov-
ed on the screening 24-hour assessment. Intuitively, it
ould seem appropriate to place more weight on frequent,
nger, and/or faster episodes of NSVT; however, there
ve been no systematic investigations of whether number
episodes and duration or ventricular rate of episodes of
SVT definitely have an impact on SCD risk.
.3.1.1.5. Maximum LV Wall Thickness. The relation-
ip between severity of LV hypertrophy and SCD has been
vestigated in several studies predicated on the concept that
e more severe the disease expression, the more likely the
dividual patient is to experience adverse events. Most, but
t all (51,399), studies have shown at least a univariate
sociation between maximum wall thickness and SCD
89,396,399), whereas other large studies have shown that
hen magnitude of hypertrophy is 30 mm, there is an
dependent association with SCD (50,161,392). Notably, 3
ports derive from overlapping samples of patients
0,127,391) have shown different strengths in the relation-
ip between wall thickness and SCD that may reflect a slight
riance in exclusion criteria, definition of other risk markers,
d the number of risk markers included in multivariate
alysis. It is crucial to recognize that the risk estimate does
t abruptly increase for patients with 30 mm wall thick-
ss but rather increases in a linear fashion (161) and appears
carry more prognostic significance in younger patients
00). With this in mind, a young adult with hypertrophy that
proaches 30 mm may have similar or greater SCD risk than
der patients with maximum wall thickness 30 mm.
.3.1.1.6. Abnormal Blood Pressure Response During
xercise. For up to a third of patients with HCM, there is an
appropriate systemic systolic blood pressure response
ring exercise testing (defined as either a failure to
crease by at least 20 mm Hg or a drop of at least 20 mm
g during effort) (89,90). It has been postulated that this
nding is a risk factor for SCD. Two studies have shown
univariate association between this finding and subse-
ent SCD (50,89,127,390). It is also unclear how thisnding is related to the well-recognized increase in dy-
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namic condition that is readily modifiable with medica-
on or mechanical procedures. It would be appropriate to
assess this particular SCD risk marker following inva-
ve therapies to relieve outflow tract obstruction, although
ere are no data in such patients.
.3.1.2. OTHER POTENTIAL SCD RISK MODIFIERS
.3.1.2.1. LVOT Obstruction. Although some studies
ve not found a significant association between LVOT
struction and SCD (47,161), other studies have found
gher rates of SCD among patients with resting gradients
30 mm Hg (127,390) and that the risk is positively
rrelated with severity of LVOT obstruction (127). Con-
rsely, relief of outflow tract obstruction through surgical
yectomy is associated with very low rates of SCD (61,321).
limitation to using LVOT obstruction as an independent
sk marker is that the obstruction in HCM is dynamic and
ghly variable from hour to hour to the extent that no
adient may be detectable during one evaluation, whereas
e next day (or even a short time later during the same day),
moderate to severe gradient may be apparent (81,401). This
riability makes it not only difficult to assess risk in the
dividual patient, but it also likely explains the difficulty in
monstrating statistical significance in smaller studies.
hether exercise-induced augmentation of the gradient is
e of the mechanisms that results in syncope and/or abnor-
al blood pressure response during exercise has not been
mpletely addressed.
.3.1.2.2. LGE on CMR Imaging. There has been con-
derable interest in promoting LGE on CMR imaging as a
tential SCD risk marker in HCM. Because LGE is
lieved to represent myocardial fibrosis or scarring, it has
en hypothesized that LGE may represent myocardium
one to ventricular tachyarrhythmia (188). Indeed, LGE
s been associated with NSVT and ventricular ectopy but
s not been associated with clinical SCD events or ICD
scharge in published studies (184,185,188). More recent
udies have shown a relationship between LGE and SCD
d heart failure but with low positive predictive accuracy
86,187). LGE is a common feature observed in patients
ith HCM, and there is no consensus on the appropriate
aging protocols or threshold for detection of LGE. Both
these features currently limit the role of LGE as an
dependent risk marker.
.3.1.2.3. LV Apical Aneurysm. A subset of patients with
CM (prevalence about 2%) develop a thin-walled LV apical
eurysm associated with regional scarring (182) and more
verse clinical events during follow-up, including progres-
ve heart failure and evolution into the end-stage phase as
ell as SCD. Although data on LV aneurysms in HCM are
mited, this abnormality may warrant consideration in SCD
sk-assessment strategies.
.3.1.2.4. Genetic Mutations. SCD may cluster in cer-
in families with HCM, and the possibility that specific
rcomere mutations may confer SCD risk has beenpothesized. Indeed, several early studies of HCM pedi-
rees implicated certain mutations as “malignant”
07,114,402,403). However, subsequent studies of less
lected consecutive patients with HCM found that it was
oblematic to infer likelihood of SCD events on the basis
the proposed mutations, because in some instances the
te of adverse events (and prevalence of associated SCD
sk markers) was lower in patients with “malignant”
utations than it was in those with mutations believed to
“benign” (95,404 – 406). The data from unselected
nsecutive outpatients suggest that most mutations are
ovel” and limited to particular families (“private” mu-
tions). Therefore, routine mutational screening would
pear to be of little prognostic value in HCM.
.3.1.3. UTILITY OF SCD RISK MARKERS IN
LINICAL PRACTICE
ther than cardiac arrest, each of the HCM risk factors has
w positive predictive value (approximately 10% to 20%)
d modestly high negative predictive value (85% to 95%).
ultiple risk markers in individual patients would intui-
vely suggest greater risk for SCD; however, the vast
ajority of patients with 1 risk marker will not experi-
ce SCD, and simple arithmetic summing of risk markers
not precise because of the uncertainty implicit in
signing a relative weight to any individual risk factor
0,51,407). Notably, in the international HCM-ICD reg-
try (55), the number of risk factors did not correlate with
e rate of subsequent appropriate ICD discharges among
esumably high-risk patients selected for ICD placement.
hese data suggest that the presence of a single risk marker
ay be sufficient to warrant ICD placement in many
tients, but these decisions need to be individualized with
gard to age, the strength of the risk factor, and the
sk-benefit of lifelong ICD therapy (55,408).
.3.2. Selection of Patients for ICDs—
ecommendations
ASS I
The decision to place an ICD in patients with HCM should
include application of individual clinical judgment, as well as a
thorough discussion of the strength of evidence, benefits, and
risks to allow the informed patient’s active participation in
decision making (Figure 4) (53–56). (Level of Evidence: C)
ICD placement is recommended for patients with HCM with
prior documented cardiac arrest, ventricular fibrillation, or
hemodynamically significant VT (55,387–389). (Level of Evi-
dence: B)
ASS IIa
It is reasonable to recommend an ICD for patients with HCM with:
a. Sudden death presumably caused by HCM in 1 or more
first-degree relatives (394). (Level of Evidence: C)
b. A maximum LV wall thickness greater than or equal to
30 mm (50,51,161,400). (Level of Evidence: C)
c. One or more recent, unexplained syncopal episodes (392).(Level of Evidence: C)
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those <30 years of age) in the presence of other SCD risk
factors or modifiers‡ (53,129). (Level of Evidence: C)
An ICD can be useful in select patients with HCM with an
abnormal blood pressure response with exercise in the pres-
ence of other SCD risk factors or modifiers‡ (89,90,390).
(Level of Evidence: C)
It is reasonable to recommend an ICD for high-risk children with
HCM, based on unexplained syncope, massive LV hypertrophy,
or family history of SCD, after taking into account the relatively
high complication rate of long-term ICD implantation. (Level of
Evidence: C)
ASS IIb
The usefulness of an ICD is uncertain in patients with HCM with
isolated bursts of NSVT when in the absence of any other SCD
risk factors or modifiers‡ (53). (Level of Evidence: C)
The usefulness of an ICD is uncertain in patients with HCM with
an abnormal blood pressure response with exercise when in the
absence of any other SCD risk factors or modifiers,‡ particu-
larly in the presence of significant outflow obstruction
(89,90,390). (Level of Evidence: C)coCD risk modifiers are discussed in Section 6.3.1.2.ASS III: HARM
ICD placement as a routine strategy in patients with HCM
without an indication of increased risk is potentially harmful.
(Level of Evidence: C)
ICD placement as a strategy to permit patients with HCM to
participate in competitive athletics is potentially harmful.
(Level of Evidence: C)
ICD placement in patients who have an identified HCM geno-
type in the absence of clinical manifestations of HCM is
potentially harmful. (Level of Evidence: C)
Although the overall rate of SCD in HCM is approximately
per year, clearly there are individuals at higher risk for
hom prophylactic therapy may be indicated. Pharmacologic
erapy has not been demonstrated to provide protection from
CD. Conversely, the ICD has proved to be effective in
rminating life-threatening ventricular tachyarrhythmias in
CM, altering the natural course of the disease and prolong-
g life.
The decision for placement of primary prevention ICD in
CM often involves a large measure of individual clinical
dgment, particularly when the evidence for risk is ambig-
us. The potential for SCD needs to be discussed with each
lly informed HCM patient and family member in the
Figure 4. Indications for ICDs in HCM. *SCD
risk modifiers include established risk factors
and emerging risk modifiers (Section 6.3.1.2).
BP indicates blood pressure; ICD, implantable
cardioverter-defibrillator; LV, left ventricular;
SCD, sudden cardiac death; SD, sudden
death; and VT, ventricular tachycardia.ntext of their concerns and anxieties and should be bal-
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D strategy. Consideration of the patient’s age is warranted,
rticularly because device complications are more likely in
ildren and young adults over the long period of follow-up
5,408).
.3.2.1. RESULTS OF ICD THERAPY IN HCM
here have been 2 reports from an international, multicenter
gistry of patients with HCM who have undergone ICD
acement on the basis of the clinical perception of SCD
fficient to justify device therapy (54,55). Among patients
ho received a device as a result of a prior personal history
cardiac arrest or sustained ventricular arrhythmia (second-
y prevention ICD), the annualized rate of subsequent
propriate ICD discharge was 10% per year. Patients with
imary prevention ICDs placed on the basis of 1 or more of
e conventional risk markers experienced appropriate ICD
erapy at a rate of approximately 4% per year (54,55).
mong these patients, who were selected for ICD placement
sed on clinical risk perceptions, the number of risk markers
esent did not predict subsequent device discharge. Whether
is is related to the highly selected population involved or
ssibly because an appropriate ICD discharge may not
cessarily be synonymous with SCD prevention is uncertain.
he relative weight of the individual risk markers in predict-
g device discharge rate has not been reported (55,408).
.3.2.2. COMPLICATIONS OF ICD THERAPY IN HCM
is important to recognize and discuss with patients potential
D-related complications (both procedural and long term)
at occur at a rate of 4% per year in patients with HCM
08). Potential early problems may include pneumothorax,
ricardial effusion, pocket hematoma, acute pocket infec-
on, and/or lead dislodgment. Late complications include
per extremity deep venous thrombosis, lead dislodgment,
fection, high defibrillation threshold necessitating lead re-
sion, and inappropriate shocks, that is, shocks triggered by
praventricular arrhythmias, sinus tachycardia, lead frac-
res or dislodgment, oversensing, double counting, and
ogramming malfunctions.
Reported rates of complications include approximately
% of patients with HCM who experienced inappropriate
D discharge; 6% to 13% who experienced lead complica-
ons (fracture, dislodgment, oversensing); 4% to 5% who
veloped device-related infection; and approximately 2% to
who experienced bleeding or thrombosis complications
5,408). The rate of inappropriate shocks and lead fractures
pears to be higher in children than in adults, largely
cause their activity level and body growth places continual
rain on the leads, which are the weakest link in the system
86). This issue is of particular concern, given the long
riods that young patients will have prophylactically im-
anted devices.
Industry-related ICD problems have affected patients with
CM. Prominent recalls have included defective generators
ading to several deaths (409) and small-diameter high-
ltage leads prone to fracture (410,411). The implant pro-
dure has been largely free of significant risk, without
ported deaths, although selected patients with extreme thpertrophy or who have received amiodarone may require
gh-energy output generators or epicardial lead systems
12).
.3.2.3. OVERALL RISK ASSESSMENT AND SELECTION
F PATIENTS FOR ICD THERAPY
he decision to recommend and pursue ICD placement is a
mplex process that can be oversimplified. The individuality
each patient and family circumstance, including level of
xiety, life situation, and views on death, and individual
sessment of the relative weight of potential benefits com-
red with potential risks must be processed for each patient.
he low positive predictive value of any of the SCD risk
ctors and the variability in the strength of data also
troduce a degree of ambiguity to the SCD risk assessment
d dramatically limit the applicability of counting the
mber of risk factors as the primary risk assessment meth-
ology. Based on the weight of evidence, plausibility, and
nsensus judgment reflecting clinical experience, it is rec-
nized that patients with massive hypertrophy, a family
story of HCM-related SCD, or recent unexplained syncope
ould probably benefit from ICD placement. Apart from
ese, it was believed that a combination of conventional risk
ctors and other risk modifiers provided the optimal identi-
cation of the subset of patients with HCM with sufficient
sk of SCD to warrant strong consideration of ICD place-
ent (Figure 4).
.3.2.4. SELECTION OF ICD DEVICE TYPE—
ECOMMENDATIONS
ASS IIa
In patients with HCM who meet indications for ICD implantation,
single-chamber devices are reasonable in younger patients with-
out a need for atrial or ventricular pacing (410,413–415). (Level
of Evidence: B)
In patients with HCM who meet indications for ICD implantation,
dual-chamber ICDs are reasonable for patients with sinus brady-
cardia and/or paroxysmal AF (413). (Level of Evidence: C)
In patients with HCM who meet indications for ICD implanta-
tion, dual-chamber ICDs are reasonable for patients with ele-
vated resting outflow gradients greater than 50 mm Hg and
significant heart failure symptoms who may benefit from right
ventricular pacing (most commonly, but not limited to, patients
>65 years of age) (283,284,367,413). (Level of Evidence: B)
ll ICDs incorporate a right ventricular lead that has both pacing
d defibrillation capabilities. ICDs are available as single-
amber, dual-chamber, or 3-chamber (i.e., cardiac resynchro-
zation therapy) devices. Whether a patient receives a dual-
amber or cardiac resynchronization therapy system depends
other considerations, including the need for atrial pacing,
hanced supraventricular tachycardia (SVT) discrimination,
ght ventricular pacing, and importantly, consideration of the
tient’s age and the subsequent longevity of the lead and ICD
stem (416). In patients with LVOT obstruction, particularly
e elderly, in whom ICDs are indicated, dual-chamber pacing
ay have the potential to reduce gradient and symptoms in some
tients (Section 6.2.2.6).
ICD leads fail at a rate of 0.5% to 1% per year, althoughere are data showing that failure rates are increased in a
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ad is needed; the old lead can remain in, which over time
aces the patient at risk for venous obstruction, or the old
ad may be removed, which carries a significant risk of
orbidity and mortality. In young patients with HCM, an
D may be needed for up to 70 years. There is no
pectation that a single lead will remain functional for that
ount of time. Thus, in general, the younger the patient, the
ore appropriate it is for single-chamber devices to be used
decrease the amount of hardware in the venous system.
Dual-chamber devices have been advocated to increase the
ility of the ICD to differentiate between SVT and ventric-
ar arrhythmias. Data to support this hypothesis are mixed
ith some studies showing no difference between inappro-
iate therapy for SVT (417,418) and others showing a
nefit (419,420). Currently, discrimination of SVT is inad-
uate as a sole justification for a dual-chamber device in
tients with HCM.
Whether cardiac resynchronization therapy devices are useful
r patients with HCM is unclear. There is a paucity of published
ta on the use of cardiac resynchronization therapy devices in
tients with HCM and end-stage heart failure (421).
.3.3. Participation in Competitive or Recreational
ports and Physical Activity—Recommendations
ASS IIa
It is reasonable for patients with HCM to participate in low-
intensity competitive sports (e.g., golf and bowling) (422,423).
(Level of Evidence: C)
It is reasonable for patients with HCM to participate in a range
of recreational sporting activities as outlined in Table 4 (224).
(Level of Evidence: C)
ASS III: HARM
Patients with HCM should not participate in intense competi-
tive sports regardless of age, sex, race, presence or absence of
LVOT obstruction, prior septal reduction therapy, or implanta-
tion of a cardioverter-defibrillator for high-risk status (58,59,
422–426). (Level of Evidence: C)
number of large cohort studies from the United States
dicate that HCM is the most common cardiovascular cause
SCD in young athletes, accounting for about one third of
ese events (58,59,425,427). The American College of
ardiology Bethesda Conference No. 36 (422,429) as well as
e European Society of Cardiology guidelines (423,429)
dicate that risk for SCD is increased during intense com-
titive sports and also suggest that the removal of these
dividuals from the athletic arena can diminish their risk.
his principle is the basis for disqualification of athletes with
CM from sanctioned high school and college sports
22,429). It should be underscored that these consensus
commendations for competitive athletes are independent of
ose for noncompetitive, informal recreational sporting ac-
vities (224).
General recommendations for recreational exercise in pa-
ents with HCM should be tailored to the individual’s desires
d abilities; however, certain guidelines prevail. For exam- clee, aerobic exercise as opposed to isometric exercise is
eferable. Patients with HCM should avoid recreational
orts in which participation is intense and simulates com-
titive organized athletics. Also, burst exertion, in which an
rupt increase in heart rate is triggered (e.g., sprinting in
lf-court basketball), is less desirable than swimming laps or
cling. Finally, it is prudent for such patients to avoid
ysical activity in extreme environmental conditions of heat,
ld, or high humidity, with attention paid to maintaining
lume status. Detailed recommendations for individual
orts appear in Table 4.
.4. Management of AF—Recommendations
ASS I
Anticoagulation with vitamin K antagonists (i.e., warfarin, to
an international normalized ratio of 2.0 to 3.0) is indicated in
patients with paroxysmal, persistent, or chronic AF and HCM
(60,430,431). (Anticoagulation with direct thrombin inhibitors
[i.e., dabigatran§] may represent another option to reduce the
risk of thromboembolic events, but data for patients with HCM
are not available (432). (Level of Evidence: C)
Ventricular rate control in patients with HCM with AF is
indicated for rapid ventricular rates and can require high doses
of beta antagonists and nondihydropyridine calcium channel
blockers (60,430). (Level of Evidence: C)
ASS IIa
Disopyramide (with ventricular rate–controlling agents) and
amiodarone are reasonable antiarrhythmic agents for AF in
patients with HCM (430,433). (Level of Evidence: B)
Radiofrequency ablation for AF can be beneficial in patients
with HCM who have refractory symptoms or who are unable to
take antiarrhythmic drugs (63–65,434,435). (Level of Evi-
dence: B)
Maze procedure with closure of LA appendage is reasonable in
patients with HCM with a history of AF, either during septal
myectomy or as an isolated procedure in selected patients.
(Level of Evidence: C)
ASS IIb
Sotalol, dofetilide, and dronedarone might be considered alter-
native antiarrhythmic agents in patients with HCM, especially
in those with an ICD, but clinical experience is limited. (Level
of Evidence: C)
AF is an important cause of symptoms, morbidity, and
en mortality in patients with HCM (57,60). Diagnosis
ay be made by an ECG during an AF episode or
casionally on ambulatory Holter monitoring; use of an
ent recorder may be helpful in some patients. Patients
ith HCM are at increased risk of AF compared with
e-matched cohorts, but AF is seldom seen in young
tients with HCM who are 30 years of age and becomes
ore prevalent with age. Risk factors for AF in HCM
clude age, congestive heart failure, and LA function,
ameter, and volume (60,436). A family history of AF is
abigatran should not be used in patients with prosthetic valves, hemodynamically
nificant valve disease, advanced liver failure, or severe renal failure (creatinine
arance 15 mL/min) [432]).
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data in patients with HCM. AF occurring in HCM may
t be associated with symptoms or hemodynamic com-
omise in one third of patients but is poorly tolerated in
any others. There is evidence that AF is an indicator of
favorable prognosis, including increased risk of HCM-
lated heart failure, death, and stroke (60,437).
Therapy for AF includes prevention of thromboembolic
roke and controlling symptoms (Figure 5). The risk of
stemic embolization is high in patients with HCM with
F but is not related to the severity of symptoms (57,60).
ccurrence of paroxysmal, persistent, or chronic AF is a
rong indication for anticoagulation with a vitamin K
tagonist (430). Whether there is a threshold for AF that
arrants anticoagulation is unresolved; however, given the
gh risk of thromboembolism in HCM, even patients with
ort episodes of AF should be strongly considered for
ticoagulation. Even a single episode of AF should be
use to consider anticoagulation because the likelihood of
current AF is high. Aspirin should be reserved for those
ho cannot or will not take warfarin or other oral
ticoagulants, but its efficacy in HCM is unestablished.
he role of LA occlusion devices in HCM is untested but
uld possibly be a future option in patients who cannot
lerate anticoagulant therapy (438).
Symptom control may be attained with adequate rate
ntrol, although many patients will require rhythm con-
ol. Rate control is best maintained by beta blockers and
lcium channel blockers. High doses of these agents may
required. Digoxin may modestly reduce ventricular rate
rest and to a lesser extent with exertion. Because there
a paucity of data on rhythm control in patients with
CM, evidence from other patient populations is extrap-
ated to HCM. However, whether patients with HCM
spond similarly to antiarrhythmic agents is not clear. The
011 ACCF/AHA/HRS Focused Updates Incorporated
to the ACC/AHA/ESC 2006 Guidelines for the Manage-
ent of Patients With Atrial Fibrillation” state that diso-
ramide and amiodarone are potential agents for rhythm
ntrol (430). The limited published data on amiodarone
ggest that it is safe and effective for patients with HCM
39 – 442). Disopyramide has been shown to be safe when
escribed for reduction of LVOT obstruction, but its
fety and efficacy in AF are not well established
57,443). Dronedarone, an antiarrhythmic agent similar to
iodarone but lacking the iodine moiety and much of the
ng-term toxicity, has been approved for use in the United
tates. There are no data regarding the efficacy of drone-
rone or the use of flecainide and propafenone in patients
ith HCM. In the CAST (Cardiac Arrhythmia Suppression
rial) trial, Class IC agents were associated with an
creased mortality in patients with CAD (444). Thus,
ution is advised when these agents are prescribed for
tients with HCM and their use should probably be
mited to individuals with an ICD. The management of
rial flutter in HCM is similar to that in other disease
ates, including the role of radiofrequency ablation.
The long-term benefits of radiofrequency ablation versusble 4. Recommendations for the
cceptability of Recreational (Noncompetitive)
orts Activities and Exercise in Patients With HCM*
Intensity Level Eligibility Scale for HCM†
gh
Basketball (full court) 0
Basketball (half court) 0
Body building‡ 1
Gymnastics 2
Ice hockey‡ 0
Racquetball/squash 0
Rock climbing‡ 1
Running (sprinting) 0
Skiing (downhill)‡ 2
Skiing (cross-country) 2
Soccer 0
Tennis (singles) 0
Touch (flag) football 1
Windsurfing§ 1
oderate
Baseball/softball 2
Biking 4
Hiking 3
Modest hiking 4
Motorcycling‡ 3
Jogging 3
Sailing§ 3
Surfing§ 2
Swimming (laps)§ 5
Tennis (doubles) 4
Treadmill/stationary bicycle 5
Weightlifting (free weights)‡ 1
w
Bowling 5
Brisk walking 5
Golf 5
Horseback riding‡ 3
Scuba diving§ 0
Skating¶ 5
Snorkeling§ 5
Weights (nonfree weights) 4
*Recreational sports are categorized according to high, moderate, and low levels
exercise and graded on a relative scale (from 0 to 5) for eligibility, with 0 to 1
dicating generally not advised or strongly discouraged; 4 to 5, probably permitted;
d 2 to 3, intermediate and to be assessed clinically on an individual basis. The
signations of high, moderate, and low levels of exercise are equivalent to an
timated 6, 4 to 6, and 4 metabolic equivalents, respectively.
†Assumes absence of laboratory DNA genotyping data; therefore, limited to
inical diagnosis.
‡These sports involve the potential for traumatic injury, which should be
ken into consideration for individuals with a risk for impaired consciousness.
§The possibility of impaired consciousness occurring during water-related
tivities should be taken into account with respect to the individual patient’s
nical profile.
Recommendations generally differ from those for weight-training machines
onfree weights), based largely on the potential risks of traumatic injury
sociated with episodes of impaired consciousness during bench-press
aneuvers; otherwise, the physiologic effects of all weight-training activities
e regarded as similar with respect to the present recommendations.
¶Individual sporting activity not associated with the team sport of ice hockey.tiarrhythmic drugs in patients with HCM remain to be
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on rates are similar between HCM and other forms of heart
sease or absence of heart disease (63–65,445). Thus,
diofrequency ablation may play a role in the management
AF, but further investigation is necessary. The surgical
aze procedure for AF has shown some limited success
46); however, whether a prophylactic or therapeutic surgi-
l maze procedure is indicated for patients undergoing other
en chest surgical procedures (i.e., septal myectomy) is
resolved.
. Other Issues
.1. Pregnancy/Delivery—Recommendations
ASS I
In women with HCM who are asymptomatic or whose symp-
toms are controlled with beta-blocking drugs, the drugs should
be continued during pregnancy, but increased surveillance for
fetal bradycardia or other complications is warranted (41,140,
447,448). (Level of Evidence: C)
For patients (mother or father) with HCM, genetic counseling
is indicated before planned conception. (Level of Evidence: C)
In women with HCM and resting or provocable LVOT obstruc-
gure 5. Management of AF in HCM. AF indicates atrial fibrillation
anent pacemaker; and PVI, pulmonary vein isolation.tion greater than or equal to 50 mm Hg and/or cardiac prsymptoms not controlled by medical therapy alone, pregnancy
is associated with increased risk, and these patients should be
referred to a high-risk obstetrician. (Level of Evidence: C)
The diagnosis of HCM among asymptomatic women is not
considered a contraindication for pregnancy, but patients
should be carefully evaluated in regard to the risk of pregnancy.
(Level of Evidence: C)
ASS IIa
For women with HCM whose symptoms are controlled (mild to
moderate), pregnancy is reasonable, but expert maternal/fetal
medical specialist care, including cardiovascular and prenatal
monitoring, is advised. (Level of Evidence: C)
ASS III: HARM
For women with advanced heart failure symptoms and HCM,
pregnancy is associated with excess morbidity/mortality.
(Level of Evidence: C)
omen with HCM safely experience pregnancy and labor with
inimal documented risks. The maternal mortality rate is
traordinarily low and limited to those patients with particularly
vanced disease (449). Nevertheless, careful evaluation of the
other and functional assessment is paramount during and just
atrioventricular; INR, international normalized ratio; PPM, per-; AV,ior to pregnancy. Usually, special medical precautions are
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omen with advanced disease, including progressive heart
ilure, severe diastolic dysfunction, VT, SVT, or marked LVOT
struction, will require the care of a high-risk maternal/fetal
edical team with close involvement of a cardiologist. For the
oman whose disease is well controlled with medical therapy
eta blockers, verapamil, or disopyramide), there should be no
terruption of therapy, but careful maternal and fetal monitoring
advised (157). For any woman of childbearing age with HCM,
is paramount that genetic counseling be advised before
nception. Such patients should be counseled prospectively
out the risks of pregnancy and discouraged if deemed neces-
ry. Careful monitoring is advisable in the first 24 hours after
livery, when large fluid shifts can lead to acute pulmonary edema
the setting of a noncompliant and hypertrophied left ventricle.
.2. Occupational Considerations
2002, the U.S. Department of Transportation Federal
otor Carrier Safety Administration published its “Cardio-
scular Advisory Panel Guidelines for the Medical Exami-
tion of Commercial Motor Vehicle Drivers.” The guide-
nes state that “irrespective of symptoms, a person should not
certified as a [commercial motor vehicle] driver if a firm
agnosis of [HCM] is made. . .” (450).(p83) Although con-
deration has subsequently been given to liberalizing this
striction, the guidelines have not yet been revised.
The criteria for the disqualification of aircraft pilots with
rdiovascular disease are set by the Federal Aviation Ad-
inistration. Currently, HCM is regarded as generally incom-
tible with the highest grade aviation license for commercial
lots, based on the unpredictable risk for impairment in the
ckpit attributable to HCM (452).
. Future Research Needs
espite progress in the understanding of the etiology and
thophysiology of HCM and in certain aspects of manage-
ent, more substantial insights into the fundamental and
inical components of HCM provide considerable opportu-
ties to improve patient outcomes. The research priorities in
CM were detailed in 2010 by a National Heart, Lung, and
lood Institute working group (453).
.1. Establishing the Cause of HCM
ver the past 20 years there have been major advances in
entification of genetic mutations that cause HCM. Contem-
rary data sets include 1,400 mutations that primarily
cur in at least 8 genes that encode protein components of
e sarcomere. Nonetheless, the genetic cause remains un-
own for a substantial proportion of patients with clinical
anifestations of HCM. Mutation-negative patients may have
he Federal Motor Carrier Safety Administration defines commercial motor
hicle as a motor vehicle or combination of motor vehicles used in commerce to
nsport passengers or property if the motor vehicle:
(a) has a gross combination weight rating of 11,794 kg (26,001 lb) inclusive
a towed unit(s) with a gross vehicle weight rating of 4,536 kg (10,000 lb); or
(b) has a gross vehicle weight rating of 11,794 kg (26,001 lb); or
(c) is designed to transport 16 passengers, including the driver; or
(d) is of any size and is used in the transportation of hazardous materials asprfined [by the Federal Motor Carrier Safety Administration] (451).V hypertrophy attributable to another genetic (or nonge-
tic) cause, with morphologic features that mimic HCM but
ith distinctive pathophysiology and clinical outcomes. Def-
ition of the cause(s) of HCM morphology in mutation-
gative patients is important for the basic understanding of
echanisms that remodel the heart and for determining
hether or not the clinical practice guidelines established for
CM are relevant in these patients. The ability to pool data
om multiple registries is encouraged.
.2. Defining the Link Between
enotype and Phenotype
he emergence of newer sequencing methodologies provides
paralleled opportunities for defining the precise mutation in
ost patients with HCM. Such information can expand our
derstanding of the relationship between genotype and
enotype in HCM, a link that remains incompletely under-
ood. Directing future efforts to identify genetic modifiers
.e., genes that influence clinical expression) and environ-
ental influences may expand understanding of the signaling
thways that are responsible for phenotypic expression of
CM and related disease states. These strategies also hold the
tential to define novel therapeutic targets that may attenu-
e the consequences of sarcomere gene mutations, so that
sease expression may be delayed or conceivably prevented.
.3. Management and Evaluation of
CM Genotype-Positive/Phenotype-Negative
elatives
ene-based diagnosis of HCM families has increased the
entification of genotype-positive/phenotype-negative indi-
duals. There are many unanswered questions about the
tural history of these patients, including the identity of
ctors that influence duration of the preclinical phase, the
kelihood of clinical identification by screening with echo-
rdiography (or CMR), the risk of SCD, and decisions about
e periodicity of clinical screening, the use of ICDs for
imary prevention, and participation in competitive sports.
ongitudinal data are needed to develop appropriate manage-
ent recommendations for this growing subset of patients. In
dition, as more information is accrued regarding the sig-
ling pathways that account for clinical manifestation asso-
ated with sarcomere protein gene mutations, the study of
erapeutic interventions aimed at preventing the emergence
disease in preclinical patients can be expected.
.4. Clinical Significance of
yocardial Fibrosis
yocardial fibrosis of the heart is increased in HCM because
an expansion of the interstitial matrix and also myocardial
placement scarring (caused by microvascular ischemia and
her factors). Consistent with histopathologic findings, se-
m biomarkers of collagen turnover are elevated in patients
ith clinically overt HCM. Recent studies in HCM models
dicate that extracellular matrix remodeling predates the
ergence of hypertrophy and may contribute to diastolic
sfunction (18). Studies are needed to ascertain whether
evention of interstitial (matrix) expansion or replacement
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tcomes such as progressive heart failure.
Replacement fibrosis and scarring can be visualized (in
vo) by CMR gadolinium contrast enhancement. Clearer
derstanding of the relationship between LGE, fibrosis, and
inical outcomes (including ventricular tachyarrhythmias
d SCD) is needed.
.5. Therapies to Directly Modify the
CM Pathophysiology
he most widely used medical therapies for patients with
CM (beta-adrenergic blockers, calcium channel blockers,
sopyramide) nonspecifically address aspects of the hemo-
namic abnormalities in patients with HCM, such as reduc-
g contractility to diminish the magnitude of outflow tract
struction. As noted above, a more sophisticated under-
anding of the links between the molecular pathophysiology
d outcome is necessary in HCM to promote the develop-
ent of more relevant and targeted treatment strategies (453).
or example, characterization of the fundamental biophysical
fects produced by different mutations in sarcomere pro-
ins, assessment of energy requirements of the heart in
CM, and assessment of the role of myocardial ischemia may
ad to interventions that alter the natural history of disease
pression.
.6. Refining Risk Stratification for SCD
s noted in this document, identifiable clinical markers are
ing used successfully in risk stratification for SCD in HCM,
sisting in recommendations about prophylactic ICDs.
onetheless, much ambiguity is often encountered in using
e current SCD risk stratification algorithm in individual
tients, and there is a need to identify additional and more
nsitive/specific risk factors. Moreover, SCD may occasion-
ly occur in “low-risk” patients without conventional risk
ctors. The assembly of larger cohorts from multiple centers
ith detailed clinical, genetic, and lifestyle information may
prove SCD risk stratification and enable more efficient use
ICDs.
.7. Comparative Assessment of
eptal Reduction Strategies
he opportunity for percutaneous strategies to reduce outflow
act obstruction in HCM was realized through the develop-
ent of alcohol septal ablation. The potential of this approach
provide clinical benefit in reducing symptoms with lower
tient morbidity and reduced healthcare expenditures has
en somewhat undermined by a concern for increased
ntricular arrhythmias following the procedure. Robust in-
rmation about the types and frequency of adverse outcomes
llowing alcohol septal ablation are needed in addition to
gorous assessment of whether these events are intrinsic to
e procedure or related to underlying hypertrophic substrate,
ncomitant coronary or other comorbid disease, or the
vanced age at which patients receive this therapy versus
yectomy. In addition, observational registries might be
eful to compare rates of HCM-related death. Such compar-
ons of short- and long-term outcomes of patients treated
ith alcohol septal ablation or myectomy surgery wouldster appropriate use of these strategies and improve patient
mptoms and outcomes.
.8. Therapies to Treat and Prevent AF and
s Associated Risks
F is a common cause of morbidity and mortality in patients
ith HCM. Anticoagulation is well established in other
uses of AF and almost certainly extends to the HCM patient
ith paroxysmal, chronic, or persistent AF. However,
hether anticoagulation should extend to those patients with
CM who are at high risk of development of AF is unclear.
addition, the relative roles of antiarrhythmic agents,
diofrequency ablation, and surgical maze procedure need
proved definition.
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